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ABSTRACT 
 
CONTRIBUTION OF MESENCHYMAL STEM CELLS IN CELL BASED 
THERAPIES 
 
Zeynep TOKCAER KESKİN 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Dr. K. Can Akçalı 
August 2010, 110 Pages 
 
Stem cell research evolved as a new hope and has gained tremendous interest in 
the last two decades to develop new strategies for many of debilitating diseases. 
Mesenchymal Stem Cells (MSCs) are multipotent cells capable of self-renewal 
and differentiating into multiple lineages such as osteocytes, adipocytes, 
chondrocytes, myoblasts, and hepatocytes. MSCs can migrate to the injured tissue 
and have immunomodulatory effects. Due to these features, MSCs have high 
therapeutic value in tissue engineering and regenerative medicine. In this thesis, 
our aim was to investigate the further contribution of the MSCs in different 
cellular therapies. We used two approaches to accomplish our aim. First, we 
investigated the possibility of obtaining functional cardiomyocytes from rat MSC 
within a shorter time period by determining the induction timing of 
cardiomyocyte differentiation of MSCs. Our data revealed that it is possible to get 
functional cardiomyocytes from in vitro MSC culture in a shorter time period than 
previously achieved. This reduction in time may provide emergency cases with 
access to cell-based therapies that may have previously been unavailable. In the 
second part of this thesis, we examined in vivo and in vitro effects of a telomerase 
antagonist, imetelstat (GRN163L) on MSCs. Telomerase activity is essential for 
the continued growth and survival of malignant cells, therefore inhibition of this 
activity presents an attractive target for anti-cancer therapy. MSCs also show 
telomerase activity in maintaining their self-renewal; therefore the effects of 
telomerase inhibitors on MSCs may be an issue of concern. Our results showed 
that inhibiting the telomerase activity does not interfere with the self-renewal and 
differentiation of MSCs under short term in vitro culture conditions. 
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ÖZ 
 
 
MEZENKİMAL KÖK HÜCRELERİN HÜCRE TEMELLİ TERAPİLERE 
KATKISI 
Zeynep TOKCAER KESKİN 
Moleküler Biyoloji ve Genetik Doktorası 
Tez Yöneticisi: Doç. Dr. K. Can Akçalı 
Ağustos 2010, 110 Sayfa 
 
 
 
Kök hücre araştırmaları tedavisi olmayan hastalıklar için yeni bir umut olmuş ve 
son 20 yılda hastalıklara tedavi geliştirmek için yeni bir strateji olarak büyük ilgi 
görmüştür. Mezenkimal kök hücreler (MKH) kendini yenileme kapasitesine sahip, 
osteosit, adiposit, kondrosit, miyoblast ve hepatosit gibi değişik hücre kökenlerine 
farklılaşabilen, hasarlı dokuya ulaşabilen ve bağışıklık sistemini baskılayıcı etkiye 
sahip hücrelerdir. Bu özelliklerinden ötürü MKHlerin doku mühendisliği ve 
rejeneratif tıptaki terapötik önemi yüksektir. Bu tezde, amacımız MKHlerin hücre 
terapilerine katkısını incelemekti. Amacımıza ulaşmak için iki yöntem kullandık. 
İlk olarak, rat MKHlerinden kardiyomiyosit farklılaşmasının daha kısa sürede elde 
edilebilirliğini, MKHlerden kardiyomiyosit farklılaşmasını indükleme süresini 
belirleyerek araştırdık. Verilerimiz in vitro  MKH kültüründen daha kısa sürede 
fonksiyonel kardiyomiyosit elde edilebildiğini göstermiştir. Süredeki bu kısalma 
acil vakaların daha önce erişimleri sağlayamadıkları hücre temelli terapilere 
erişimini sağlayabilecektir. Tezin ikinci bölümünde telomeraz antagonisti olan 
imetelstat’ın (GRN163L) MKHler üzerindeki in vivo and in vitro etkilerini 
araştırdık. Telomeraz aktivitesi malign hücrelerin büyüme ve hayatta kalmaları 
için gereklidir, bu nedenle bu aktivitenin engellenmesi kanser tedavisi için çekici 
bir hedef oluşturmaktadır. MKHler de kendilerini yenilemek için telomeraz 
aktivitesine sahiptirler ve telomeraz inhibitörünün MKHler üzerindeki etkisi kesin 
olarak bilinmemektedir. Sonuçlarımız, telomeraz aktivitesinin engellenmesinin 
kısa süreli in vitro kültür koşullarında MKHlerin kendini yenileme ve farklılaşma 
potansiyellerini etkilemediğini göstermiştir.  
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CHAPTER 1 
 
INTRODUCTION 
 
 
 
 
Radiometric age dating indicates that the world is 4.5 billion years old and 
the origins of first human beings date back to 200.000 years ago. Throughout 
these 200.000 years, human beings have been facing with many problems. 
Majority of these problems have been caused by the humans themselves in the 
past and present such as pollution, war and feminine. In the last 50 years or so, 
humans have been facing another problem, aging. Aging is the result of the 
increased life quality due to the technological improvement to diagnose and treat 
diseases. According to World Health Organization’s 2008 health report 85% of 
the world population is supposed to be over the age of 60 by 2050 while today the 
mean life expectancy in the world is over 75 years of age 
(http://www.who.int/whr/2008/whr08_en.pdf). In this chamber of globalization, 
urbanization and aging the incidence of chronic and non-infectious diseases now 
are the main health concerns of the population, like cancer, chronic heart diseases 
and diabetes. Moreover, together with the increase at life span more than 50% of 
the people above age 70 have more than one chronic disease. Thus, treatment of 
these chronic diseases is very important for a healthy future. 
 
Stem cell research evolved as a new hope and has gained tremendous 
interest in the last two decades to develop new strategies for many of these 
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diseases. Applications involving the use of stem cells in humans that might have 
been considered “science fiction” fewer than 20 years ago are now being utilized 
with a great success rate (Akar et al 2006). In this thesis, our aim was to 
investigate the contribution of the mesenchymal stem cells (MSCs) in cellular 
therapies. We used two approaches to accomplish our aim: 
 
i) directly by determining the induction timing of cardiomyocyte 
differentiation of mesenchymal stem cells and; 
ii)  indirectly by examining the in vitro effects of a telomerase 
antagonist, imetelstat (GRN163L) on mesenchymal stem cells.  
 
Introduction section starts with a brief explanation of the stem cells. 
Embryonic stem cells, induced pluripotent stem cells and adult stem cells will be 
introduced. Among the adult stem cells, mesenchymal stem cells will be discussed 
in detail including their use in cellular therapy. Finally, the structural and 
functional features of telomerase enzyme will be analyzed. 
 
1.1  Stem cells 
 
Stem cells are group of cells that are able to self-renew and differentiate 
into several lineages to form specialized somatic cells (Morrison et al 1997, 
Weissman 2000; Till and McCulloch 1961). Stem cells are able to accomplish 
these tasks by undergoing symmetric and/or asymmetric cell division (Preston et 
al 2003). Symmetric division yields two daughter stem cells having the same 
properties of stemness which are undifferentiated and have the capacity to 
differentiate into other lineages. If there is a requirement for differentiated somatic 
cells, then a stem cell undergoes asymmetric division to yield a progenitor cell 
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and an undifferentiated copy of itself to maintain the stem cell pools of the body. 
Stem cells can be categorized based on their time of onset. Embryonic stem cells 
are present on in the very early part of the embryonic development, but germ line 
and adult stem cells become active later in the development and post nataly 
respectively. Better categorization of the stem cells can be made based on their 
potencies. Embryonic stem cells are pluripotent, which can form all the cell types 
from all body lineages where as adult stem cells are multipotent and able to 
produce multiple lineages. 
 
1.1.1 Embryonic Stem Cells 
 
After fertilization, zygote undergoes serial divisions during the embryonic 
development. At the blastula stage, cluster of cells form inner cell mass (ICM) 
where embryonic stem cells are obtained (Evans and Kaufman, 1981, Martin 
1981, Thomson et al, 1998, Reubinoff et al 2000). Embryonic stem cells are 
pluripotent and can differentiate into any of the cells belonging to three germ 
layers, endoderm, mesoderm and ectoderm. (Figure 1.1.1.1). Furthermore, they 
can maintain their pluripotency for many passages without losing their genetic 
integrity (Burdon et al 2002, Smith 2001, Keller 2005). 
 
ESCs form teratomas in vivo, which contains cell types from all germ 
layers (Wobus and Boheler 2005). X chromosome is active and ESCs do not 
undergo X inactivation until they are differentiated (Yang et al 2007). ESCs 
require a feeder layer composed of irradiated human or mouse embryonic 
fibroblast (MEF) cells. Feeder layers not only provide better attachment but also 
secrete growth factors for their maintanence (Amit et al 2003). In addition, mouse 
ESCs require leukemia inhibitory factor (LIF) to maintain their undifferentiated 
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state in vitro while human ESCs need FGF-2 (Odorico et al 2001, Pera and 
Trounson 2004, Keller 2005). When ESCs are removed from the feeder layers, 
some cells start differentiating spontaneously and some of them remain 
undifferentiated. These cells form clusters called embryoid bodies which are 
unique features of ESCs in suspension cultures. ESCs express transcription factors 
such as Oct4, Sox2 and Nanog which are important to keep them undifferentiated 
and pluripotent (Mitsui et al 2003, Strumpf et al 2005, Kuroda et al 2005, Rodda 
et al 2005). Human ESCs also express SSEA3 and 4 on their surfaces as markers 
of their undifferentiated state. They have active telomerase enzyme (Semb 2005, 
Hiyama and Hiyama 2007) that is rapidly reduced upon the differentiation 
(Armstrong et al 2005). 
 
ESCs are important tools for studying embryogenesis, understanding the 
mechanisms of genetic diseases and for cellular therapies. There are severe ethical 
problems when human ESCs are considered despite the fact that these embryos 
are leftover embryos obtained from IVF clinics. In addition, the risk of tumor 
formation and immune rejection also the problems that need to be solved.  
 5 
 
Figure 1.1.1 1 Characteristics of ESCs ©2006 Terese Winslow 
(http://stemcells.nih.gov/info/2006report/2006Chapter1.htm) 
 
1.1.2 Induced Pluripotent Stem Cells  
 
The problems that are associated with ESCs prompted the researchers to 
investigate new sources of stem cells that have the features of ESCs. Attempts 
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finally reached to a success in 2006 when two Japanese scientists, Takahashi and 
Yamanaka announced the induction of pluripotent cell from normal somatic cell. 
Their study revealed that, when mouse fibroblast cells were transfected with 
lentiviral vectors carrying Oct-4, Sox-2, Klf-4 and c-myc, the cells became 
pluripotent and this process was named as “Induced Pluripotent Cells (iPS)”. 
These four factors are called as “Yamanaka Factors”. In addition, iPS cells form 
embryoid bodies, regain their telomerase activity, elongate their telomeres and 
form teratomas in vivo, but more importantly they are capable of restarting the 
mouse developmental process after being injected into a blastocyst. When results 
of their study were first published, it opened a new era and raised hopes to obtain 
patient specific pluripotent stem cells. Afterwards studies towards better 
understanding the induced pluripotent stem (iPS) cells and their uses have gained 
tremendous interest. In 2008 iPS cells were developed by using human fibroblasts 
as a source (Park et al 2008, Takahashi et al 2008, Yu et al 2008). Several 
different cell types like pancreatic beta cells, dermal fibroblasts and keratinocytes 
(Lowry et al 2008, Stadtfeld et al 2008, Aasen et al 2008) were also used as a 
source with different transfection efficiencies. There are also some drawbacks in 
iPS cells. All these studies were employing retroviral vectors which might have 
mutagenic effects. In addition, introducing c-myc raised considerations against 
generation of tumors. As the main aim of the induced pluripotency was to 
generate patient specific cells for cell therapy, to improve the methods of iPS cell 
generation have become one of the fasted evolving areas of stem cell research. To 
tackle these problems drug induced systems, addition of N-myc instead of c-myc 
and using strategies without viral vectors (Wernig et al 2008, Nakagawa et al 
2008, Okita et al 2008) have been utilized. A successful system employed 
piggyBac transposase to generate iPS cells. In this system, Yamanaka factors 
were inserted by a single cassette controlled by tet/rtTA. By this way the 
expression of the transgenes were conditionally controlled. After a successful 
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induction was generated, the genes inserted at the first transfection were removed 
with a second transposase transfection (Woltjen et al 2009). However at the end of 
all protocols the morphological, genetically and functional properties of iPS cells 
should be checked according to their similarities with ESCs. Recent studies also 
revealed that the cells which are reprogrammed into iPS cells retain their initial 
epigenetic codes that may affect their differentiation properties (Polo et al 2010, 
Kim et al 2010). Polo et al (2010) showed that continuous passaging reduced the 
differences between differentiation capacities into different lineages and the 
transcript identities between ESC and iPS cells derived from muscle, blood and 
fibroblast origins. 
 
Although there are some drawbacks, using iPS cells in cellular therapies is 
one of the most promising options, at least in animal models. Alpio et al (2010) 
achieved to reduce high glucose levels in two different mouse models for diabetes 
mellitus by using differentiated stem cells obtained from iPS cells. In a mouse 
spinal cord injury model iPS cells were also used to induce neural differentiation 
and contributed to remyelination, formed functional neurons and astrocytes (Tsuji 
et al 2010). In addition, there are several studies that employ iPS cells 
successfully in the models of cardiovascular regeneration (Nelson et al 2009, 
Narazaki et al 2008, Zhang et al 2009) as well as Parkinson’s disease (Wernig et 
al 2008). 
 
1.1.3 Adult Stem Cells 
 
Adult stem cells (ASCs), also known as somatic stem cells, are found in 
organs and tissues and maintain homeostasis. Compared to ESCs, they are more 
differentiated and their potential is more limited (multipotent vs pluripotent). 
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There are ASCs unique for almost all tissue types such as blood, bone, intestine, 
brain, liver and heart (Figure 1.1.3.1). Although tissue specific stem cells have 
their own specific markers, but they are not universal markers for all ASC types. 
Since, ASCs are quiescent cells, retention of DNA labeling dyes like BrdU or 
histone-GFP is used to overcome such identification problems (Tumbar et al 
2004, Kiel et al 2007). 
 
 
Figure 1.1.3 1 Adult Stem Cells (Raghunath et al 2005) 
 
The first discovery of ASCs leads back to 1950s when irradiation studies 
were performed to find a cure after atomic bomb sent to Hiroshima and Nagasaki. 
Scientists discovered that, when mice were severely irradiated to deplete their 
bone marrow cells, they showed the same symptoms with the people survived 
after atomic bomb. If they were injected again with bone marrow of another 
mouse on the other hand, the whole blood system was regenerated (Lorenz et al 
1951, Ford et al 1956, Nowell et al 1956, Gengozian et al 1957). These initial 
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studies lead to the discovery and characterization of the hematopoetic stem cells 
(HSCs) (Wu et al 1963, Sprangrude et al 1988).  
 
HSCs are the most widely studied ASC type. They express CD34, CD117, 
Sca-1 as the surface markers (Kim et al 1998, Negrin et al 2000). They are able to 
differentiate into several cell types other than blood cells such as muscle cells, 
cardiomyocytes, neurons and hepatocytes (Ferrari et al 1998, Peterson et al 1999, 
Brazelton et al 2000, Jackson et al 2001). One of the main aims of bone marrow 
(BM) transplantation is actually the transplantation of HSCs. BM transplantation 
is considered as an effective treatment in many different hematopoetic diseases 
including malignancies. However HSC transplantation still has some draw backs 
mainly due to the immune rejection manifested as graft versus host disease 
(GVDH).  
 
There are also tremendous amount of cell removal in the intestines. 
Therefore intestines are also another source of stem cells. Intestinal stem cells 
(ISCs) are localized in the crypts (Marshman et al 2002) and responsible for the 
maintenance of different cell types of the intestines. Their localization is believed 
to be at the +4 position according to the Paneth cells at the bottom of the crypt as 
shown by Potten (1974) and Marshman et al (2002). Several molecules were 
identified a intestinal stem cell marker like musashi-1, sFRP5, Dcamkl1, 
prominin1/CD133 and Lgr5 (Kayahara et al 2003, Asai et l 2005, Gregorieff et al 
2005, Giannakis et al 2006, Barker et al 2007, Snippert et al 2009, Sato 2009). 
Among these markers Lgr5, which is an orphan G protein coupled receptor, is 
widely accepted as an intestinal stem cell marker since 2007 (Barker et al 2007).  
 
Neural stem cells (NSCs) are found in the neural tissue generating 
neurons, astrocytes and oligodendrocytes and can be isolated from sub-ventricular 
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zone of the brain (Kokavay et al 2008). Although the clues about their presence 
were discovered in 1960s, the idea of brain can not regenerate was dominant until 
1992. First clues about the functionality of NSCs were gathered when Reynods 
and Weiss (1992) discovered that the cells taken from adult mice brain could be 
stimulated in vitro with epidermal growth factor and they were able to proliferate 
and form neurons and astrocytes. Six years after, the proliferation of the cells in 
hippocampus and dentate gyrus of adult humans were demonstrated from the 
autopsy samples taken from the ex-patients treated with BrdU (Eriksson et al 
1998). The mostly known markers of neural stem cells are Sox2, GFAP, Pax6, 
LeX and nestin (Kokavay et al 2008, Conti and Cattaneo 2010). Studies 
performed in several animal models of neurological diseases including 
Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, multiple sclerosis 
as well as spinal cord injury models revealed the success in cellular therapy 
models by using NSCs indicating their functional role in maintenance (Ronaghi et 
al 2010, Kim and Vellis 2009 and Taupin 2008).  
 
In addition to ISCs, NSCs and HSCs there are several somatic stem cells 
as well and one of them is mesenchymal stem cells (MSCs) which are also 
localized mainly in BM like HSCs. In the next section MSCs will be described in 
detail. 
 
1.1.4 Mesenchymal Stem Cells 
 
Mesenchymal stem cells (MSCs), also known as bone marrow stromal 
cells or mesenchymal stromal cells were discovered by the pioneering studies of 
Friedenstein in 1968. During the in vitro culturing of HSCs, it was discovered that 
there was a different type of cell in the bone marrow other than HSCs with 
fibroblastic morphology.  They were able to attach to the culture plate were 
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forming colonies which were afterwards named as colony forming unit 
fibroblasts, CFU-F (Lanotte et al 1981). Moreover, they were also able to 
differentiate into bone, adipose, cartilage and muscle tissue (Figure 1.1.4.1). Later 
on, these adherent, fibroblastic and colony forming cells were first named by 
Owen as stromal stem cells (1988) which were then finally called as mesenchymal 
stem cells by Caplan (1991). First characterization study of MSCs was performed 
by Pittenger et al in 1999 obtained from human bone marrow aspirates. The BM 
aspirate was first separated according to the density gradient and plated 
afterwards. Attached cells were counted according to their colony formation 
capacities and when proportioned to the total cell number, only 0.001 to 0.01% of 
the nucleated cells formed colonies. Moreover, they have shown that MSCs were 
positive for CD29, CD90, CD71 and CD106 and negative for CD45, CD14 and 
CD34. Furthermore these cells were able to undergo 40 population doublings 
(PD) in vitro within 10 weeks. 
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Figure 1.1.4 1 MSC multilineage differentiation potential (Caplan and Bruder 
2001) 
 
 Other than bone marrow, MSCs were also isolated from many other 
sources such as adipose tissue, umbilical cord blood, placenta and even from 
dental pulp. However, studies revealed that MSCs from these sources had 
different CD marker expressions, phenotypes and PD. These results forced the 
scientific world to define certain criteria in identifying these cells. International 
Society for Cellular Therapy published a position paper by Dominici et al (2006) 
and set following features for MSCs. MSCs should be positive for CD73, CD90 
and CD105, negative for CD19, CD34, CD45, CD11a and HLA-DR. In addition, 
MSCs should be isolated from fresh tissue and should attach to the plastic culture 
plates and differentiate into adipocytes, chondrocytes and osteocytes in vitro.  
 
An important feature of MSCs is their homing capacity. Homing is defined 
as the migration of these cells to the site of injury. In the homing process of 
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MSCs, chemokines, cytokines and receptors on their surface were shown to be 
important (da Silva Meirelles et al 2008). When inflammation occurs at the site of 
injury, the gradient of cytokines and chemokines increase and the expression of 
chemokine receptors mediate the migration of MSCs to the injured tissue (Salem 
and Thiermann 2010). Especially CD44 was found to be important in homing of 
both mouse and human MSCs (Herrera et al 2004, Sackstein et al 2008). In 
addition, CXCR4 and VCAM-1 (CD106) had also a critical role in the migration 
of the MSCs (Segers et al 2006, Shi et al 2007, Hung et al 2007). It was also 
shown that MSCs can activate matrix metalloproteases to enter to the tissue from 
blood to localize the niche at the site of injury (De Becker et al 2007). 
 
MSCs also have important antiapoptotic and immunomodulatory effects, 
which makes them non immunogenic. In animal models when the MSCs were 
injected to the scarred tissue, they were able to reduce the apoptotic rate of the 
surrounding cells, which were mediated by the secretion of several growth factors 
like VEGF, FGF2 and TGF-β especially in hypoxic conditions (Togel et al 2007, 
Parekkadan et al 2007, Block et al 2009). When immunomodulatory effects are 
considered, it was shown that the proliferation of the T-cells were inhibited during 
in vitro co-culturing (Di Nicola et al 2002, Krampera et al 2003, Le Blanc et al 
2003). Furthermore, not only cytotoxic and helper T cells but also natural killer 
cells, B-cells and immature dendritic cells were found to be affected by MSCs. 
The immunomodulatory effects of MSCs on T-cells and NK cells were associated 
via secretion of molecules like TGF-β, PGE2 and IL10. Whereas their effect on 
B-cells was found to be indirect, via the modulation of plasma cells by leading the 
inhibition of immunoglobulin secretion (Sotiropoulou et al 2006, Nasef et al 
2007, Rafei et al 2008, Nemeth et al 2009, da Silva Meirelles 2009). 
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MSCs are important source for cellular therapies for the following reasons: 
i) Their well defined markers enable to obtain with high purity, 
ii)  They can easily be expanded in vitro with high numbers without 
losing their properties, 
iii) They can differentiate into different cell types,  
iv) They can migrate to the injured site in vivo,  
v) They have immunosuppressive effects that make their use possible 
in allogeneic grafting and off-shelf use. 
These special features of MSCs make them good candidates in regenerative 
medicine and cellular therapies.  
 
1.1.5 Mesenchymal Stem Cells in Cellular Therapies 
 
In the literature there are many studies investigating the regenerative 
capacities of MSCs in different disease models generated by employing different 
non-human animal species. Cardiac regeneration, liver regeneration, kidney 
regeneration, autoimmune diseases and graft versus host disease (GvHD), 
neurological diseases, pulmonary diseases, osteogenic diseases, and cartilage 
repair are the most widely studied conditions. Moreover MSCs are also being 
investigated extensively by clinical trials, mostly in United States, Europe and 
East Asia. Some of the clinical trials are studying their use in neurological, liver, 
bone, heart diseases, GvHD and some autoimmune diseases like diabetes and 
Chron’s disease. In the following section, the application of MSCs in different cell 
based therapies will be discussed and a particular attention will be given to their 
roles in heart diseases. 
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1.1.5.1 MSCs in renal injuries 
 
Kidney injuries if left untreated can progress to acute kidney failures 
followed by chronic kidney failures. At the end stage of renal disease dialysis or 
kidney transplantation is needed. Renal injuries could be due to immunological 
problems or to ischemia (Salem and Thiemermann 2010) suggesting the 
importance of restoring the microvasculature (Bussolati et al 2008). Treatment of 
kidney injuries requires either an immunomodulatory effect or replacement of the 
scared tissue. Therefore, MSCs are good candidates in curing kidney diseases. In 
the sheep model of ischemia reperfusion injury, it has been shown that the 
intraarterially injected MSCs differentiated into tubular and glomerular cells 
(Behr et al 2007). In a previous study performed with a rat model of ischemia 
reperfusion injury, the restoration of renal function was also observed after MSCs 
were introduced by intracarotid administration. However, this improvement was 
found to be a result of immunomodulatory action of MSCs as no differentiation 
was reported (Tögel et al 2005, Lange et al 2005). In recent studies performed 
with human umbilical cord derived MSCs similar result was obtained indicating 
the improvement of renal failure via immunomodulatory effects of MSCs (Chen 
et al 2010, Cao et al 2010). In this immunomodulatory activity homing of the 
MSCs to the injury site was found to be important. It has also been shown that the 
way of the administration of MSCs is also important for their immunomodulatory 
effect. In a rat model of injury better immunomodulatory effects were obtained 
when MSCs were introduced intraarterially than intravenously (Zonta et al 2010). 
Also in the homing of MSCs in renal injuries CXCR4 and CD44 were found to be 
important (Ji et al 2004, Herrera et al 2007). 
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1.1.5.2 MSCs in liver injuries 
 
Although liver is able to regenerate upon injury, in the case of end stage 
liver injuries also require transplantation which may take very long time to find a 
donor. Therefore, cellular therapies are also important in liver injuries to replace 
the need for transplantation. Since isolation and culture of hepatocytes at efficient 
amounts is not possible in vitro (Serralta et al 2003, Serralta et al 2005), cellular 
therapies involving stem cells have an important role in curing liver diseases. 
Among the stem cells, MSCs receive special attention since their differentiation 
into hepatocyte like cells were reported (Chamberlain et al 2007, Sato et al 2005, 
Lee et al 2004). 
 
Differentiation of MSCs into hepatocytes was reported both in vitro and in 
vivo. These hepatocytes were positive for the hepatocyte markers and found to be 
functional evidenced by their secretion of albumin and storing glycogen 
(Chamberlain et al 2007, Lee et al 2004, Schwartz et al 2002). 
Immunomodulatory effects of MSCs were also found to be important during liver 
regeneration. It was shown that engraftment of the MSCs into the liver, but not 
differentiation, stimulated proliferative and regenerative properties of the liver 
(Banas et al 2008, Parekkadan et al 2007, Caplan and Dennis 2006). In the murine 
injury models of carbontetrachloride treatment or partial hepatectomy the effect of 
MSCs on hepatic stellate cells were demonstrated, reducing fibrosis (Cavalho et al 
2008, Abdel Aziz et al 2007, Zhao et al 2005, Sakaida et al 2004). Chamberlain et 
al (2007) also demonstrated that when the MSCs were administered by 
intrahepatic injection they formed hepatocytes more efficiently compared to 
intraperitoneal administration. 
 
The cytokines that are responsible in the differentiation, homing and 
antifibrotic effects of MSCs were also investigated. FGF-4 and hepatocyte growth 
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factor (HGF) were found to be important in the differentiation of MSCs into 
hepatocytes (Dong et al 2010, Parekkadan et al 2007) while TNF-α and IL-6 were 
found to be important in antifibrotic effects (Pulavendran et al 2010, Parekkadan 
et al 2007). The expression of matrix metalloproteinases by MSCs was also found 
to be important in the reduction of fibrosis (Fang et al 2004, Sakaida et al 2004, 
Oyagi et al 2006). During the homing of MSCs to the injured liver it was 
demonstrated that CXCR4 and CCR9 were important molecules (Chen et al 
2009). 
1.1.5.3 MSCs in GvHD 
 
GvHD is an inflammatory reaction caused by the T-cells of the host 
against the donor tissue HLAs after the transplantation which results in the 
rejection of the transplant (Flomenberg et al 2004, Goulmy et al 1996). 
Interestingly, MSCs were found to be very effective in suppressing the immune 
reaction during GvHD (Koç et al 2000, Frassoni et al 2002, Le Blanc et al 2004). 
 
The inhibitory role of MSCs against GvHD depends on the effects of 
MSCs on dendritic cells, T cells, B cells and NK cells.  The main inhibitory effect 
was found to be via dendritic cells, thereby preventing the antigen presentation 
(Reddy et al 2005). The interaction between antigen presenting cells and T-cells 
as well as the signaling mediated via co-stimulatory factors like CD28, ICOS and 
CD40 cause the initiation of immunological response against the graft (Blazar et 
al 2001, Blazar et al 1997). MSCs lacking co-stimulatory molecules like CD40 
were not able to contact with the host immune cells (Tse et al 2003). When T-
cells and MSCs were cultured together it was demonstrated that the release of 
IFN-γ from inflammatory Th1 cells decreased while IL-4 secretion from anti-
inflammatory Th2 cells increased. Moreover, when MSCs were cocultured with 
activated T cells, PGE-2 secretion by MSCs was found to be increased and T-cell 
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inhibition was observerved. The same effect couldn’t be observed when the MSCs 
were cocultured using PGE-2 inhibitors suggesting the importance of PGE-2 
synthesis by MSCs (Aggarwal and Pittenger 2005). 
 
In a baboon model of skin transplantation, it was shown that the MSCs 
suppress T-cells and enabled graft survival with a single intravenous 
administration (Bartholomew et al 2002). At murine heart transplantation model, 
i.v. injected MSCs prolonged the survival of the transplanted heart which was 
shown to be due to the regulatory effects of MSCs on Th1 and Th2 (Zhou et al 
2006). Treg cells were shown to be induced by MSCs at another study using rat 
heart transplantation model mediating the graft survival (Casiraghi et al 2008).  
 
The immunomodulatory effect of MSCs on immune system was also 
demonstrated in human cancer patients and GvDH patients after bone marrow 
transplant (Koç et al 2000, Frassoni et al 2002, Le Blanc et al 2004). Le Blanc et 
al (2004) also reported that the MSCs administered to the patient could be of any 
type of HLA antigens. MSCs were administered twice after transplantation and 
fully recovered within a year. A recent study reported the use of MSCs with the 
bone marrow transplant patients irresponsive to immunosuppressors and they 
have also demonstrated the regression of the disease after injection of MSCs twice 
(Lim et al 2010). 
 
1.1.6 Mesenchymal Stem Cells in Cardiac repair 
 
According to the World Health Statistics Report published by WHO in 
2008, ischemic heart diseases have the highest mortality rate among all diseases 
today and 20 years later (http://www.who.int). Therefore, the treatment of heart 
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diseases is very important to provide a better living to the patients. Ischemic heart 
diseases are characterized by a shortage in the blood supply to the different 
regions of the heart. Cardiomyocytes in these regions go under necrosis and 
apoptosis which is called infarction. Although heart tissue renews itself very 
slowly by the help of cardiac stem cells, the regeneration rate is very slow to 
replace the damaged cardiac muscle with the healthy new cardiomyocytes (Oh et 
al 2003, Beltrami et al 2003). If left untreated at its end stage heart transplantation 
is the only thereupethic option. 
 
Taylor and Jones (1979) reported the generation of cells, having 
mesenchymal phenotypes after several weeks, when 3T3 and 10T ½ cells were 
treated with 5-azacytidine which incorporates and leads the methylation of DNA 
reverting the cells to a more pluripotent state. Based on their findings in 1995, 
Wakitani et al published the first paper about the generation of cardiomyocytes in 
vitro from rat BM derived MSCs. Later on several studies were perfomed which 
reported the successful differentiation of MSCs into cardiomyocytes (Makino et al 
1999, Bittira et al 2002, Xu et al 2004). 
 
In vivo studies with different animal models were performed to reveal the 
effect of MSCs in cardiovascular diseases. Shake et al (2002) showed the 
differentiation of MSCs expanded from swine BM, into functional 
cardiomyocytes when injected into the infracted swine myocardium. In a canine 
model it was observed that the intracardialy injected MSCs were differentiated 
into smooth muscle cells and endothelial cells rather than cardiomyocytes 
however they have observed a better functionality at the infracted area (Silva et al 
2005).  In a myocardial infarct model it was demonstrated that when the rats were 
treated with MSCs, the infracted area get significantly smaller 4 weeks after the 
treatment and the MSCs that were labeled prior to the treatment were expressing 
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cardiac markers such as cardiac troponin and smooth muscle actin (Tang et al 
2006). In a similar mouse model the in vivo effects of human MSCs obtained from 
the patient underwent ischemic heart disease were tested in which the infarct size 
and heart functions were assessed with MRI. According to the results of the study, 
MSCs were able to home to the scar tissue and improve the function of the left 
ventricule by differentiating into smooth muscle and endothelial cells as well as 
cardiomyocytes (Robert et al 2007). Administration ways and times were also 
investigated. Introducing MSCs by transendocardial electromechanical-guided 
delivery was more efficient than intracoronary delivery (Perin et al 2007) and it 
was demonstrated that if the MSCs were delivered to the heart 1 week after 
infarction better results were obtained in cardiac function and formation of blood 
vessels when compared to 1 hour and 2 weeks delivery (Jiang et al 2008). 
Moreover, there are studies which claim the regenerative effect of MSCs to their 
paracrine effects. MSCs that were genetically modified for the overexpression of 
Akt, exerted a better curing effect on the left ventricles of animal myocard 
infarction models (Lim et al 2006, Mangi et al 2003). Also, according to another 
study, the secretion of HGF from MSCs were triggered the migration of cardiac 
stem cells to the site of infarction and regeneration (Urbanek et al 2005). 
 
Besides animal models, transplantation of MSCs had been performed to 
patients with myocardial infarction, who showed improved myocardial activity 
after the transplant (Katritsis et al 2005). The results of a clinical trial revealed 
that the function of left ventricle in myocardial infarction patient treated with 
autologous MSCs, was improved (Wollert et al 2004, Chen et al 2004). There are 
clinical trials going on that employ MSCs in the treatment of myocardial 
infarction. A recent trial to be carried on in France is still recruiting patients to 
investigate the administration of the MSCs intracardially (Phase1/2 study), yet 
another trial is investigating the intravenous administration (Phase 2 study) 
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(http://clinicaltrials.gov). Today there are 21 clinical trials either completed or 
recruiting patients that investigate the treatment capacities of MSCs in heart 
diseases. By the help of these in vivo and in vitro studies and clinical trials, the 
theurapeutic potential of MSCs in cardiac repair will be better understood. 
 
1.2 Telomeres and Telomerase 
 
Although the understanding of telomeres and telomerase goes back to 
1880s, the first real evidence was discovered by Elizabeth Blackburn in 1978, 
who was awarded with Nobel Prize in 2009 with her colleagues for their studies 
on telomeres and telomerase.  
 
Telomeres were identified in Tetrahymena thermophila with their unique 
sequence of TTGGGG (Blackburn and Gall 1978) which were present at the ends 
of the chromosomes and protect them from degradation. Later on, the telomeric 
sequence of Tetrahymena was ligated to the end of a budding yeast plasmid and it 
was observed that the sequence was replicated and also protected the plasmid 
ends. When the duplicated sequences were separated from the Tetrahymena 
sequences it was discovered that they were the yeast telomeric fragments (Szostak 
and Blackburn 1982). Further studies revealed the presence of a reverse 
transcriptase enzyme named telomerase which was composed of RNA and a 
protein subunit (Greider and Blackburn 1985, Greider and Blackburn 1987, 
Greider and Blackburn 1989) (Figure 1.2.1).  
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Figure 1.2 1 Elongation of telomeres by the enzyme telomerase (Manthon and 
Lloyd, 2001) 
 
 
 
It is now known that mammals have the conserved telomeric sequence of 
TTAGGG (Moyzis et al 1988) and shortening of telomeres are associated with 
replicative senescence and aging of somatic cells (Lundblad and Szostak 1989, 
Harley et al 1990, Allsopp et al 1992) and replicative senescence can be overcame 
due to genomic instability and reexpression of telomerase enzyme (Hayflick 1965, 
Counter et al 1992, Kim et al 1994). The telomeres can be upto 15 kb in humans 
and at the end of the telomeric double stranded repeats a G-rich sequence is 
present which forms the T-loop that packages the chromosome ends and protects 
from 5’- 3’exonucleases activity together with the shelterin complex (Sullivan and 
Karlseder 2010, Gilson and Ségal-Bendirdjian 2010, Verdun and Karlseder 2007, 
de Lange 2005).  
 
Shelterin complex that protects the chromosome ends is composed of six 
subunits (de Lange 2005). These factors are TRF1, TRF2, POT1, TIN2, TPP1 and 
Rap1 (Chong et al 1995, Bilaud et al 1996, Broccoli et al 1997, Kim et al 1999, 
Li et al 2000, Baumann and Cech 2001, Houghtaling et al 2004). These proteins 
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function together to form the T-loop and prevent telomerase from binding after 
adequate elongation of the telomeres (de Lange 2005). 
 
Like shelterin complex that protects the telomeres, telomerase enzyme that 
elongates them is also a complex. Besides from its well known protein subunit 
telomerase reverse transcriptase (TERT) and telomerase RNA (TERC), it contains 
an RNA binding protein dyskerin (Cohen et al 2007). The three subunits of 
telomerase enzyme have to be packaged in the Cajal bodies which are then carried 
to the telomeres by telomerase cajal body protein1 (TCBP1) (Cristofari et al 2007, 
Venteicher et al 2009). At telomeric end binding of the proteins reptin and pontin 
provides the correct structure to the telomerase complex which then initiates the 
elongation of the telomeres (Venteicher et al 2008). 
 
The elongation of telomeres is important for the maintenance of the cell. 
Therefore, to gain the telomerase enzyme activity provides a survival advantage to 
the cell. Stem cells undergo division and proliferation whenever their residing 
tissue requires regeneration. Therefore the presence of telomerase holoenzyme is 
also important for the maintenance of the stem cells pools and tissue regeneration.  
 
1.2.1 Telomeres, Telomerase and Cancer 
 
Hayflick et al (1961) showed that the somatic cells were able to replicate 
only for a limited number of passaging in vitro, which is called replicative 
senescence (Hayflick 1965). It was also shown that replicative senescence was 
due to the loss of telomeres which provide the genomic stability to the 
chromosomes. Today, it is known that somatic cells do not express telomerase 
which is essential for the maintenance of the telomeres and serves as a tumor 
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suppressor to prevent the proliferation of the cells having defects in their genomes 
(Li et al 2005). However when telomerase was introduced to senescent somatic 
cells it was observed that they could overcome replicative senescence and start 
dividing unlimitedly (Bodnar et al 1998). Moreover, in vivo studies performed 
with mouse models demonstrated that when telomerase was overexpressed, the 
mice formed more tumors compared to the wild types. If the mice were resistant 
to tumor formation, prolonged life span and increased stem cell activity were 
reported (Tomas-Loba et al 2009, Sarin et al 2005, Gonzalez-Suarez et al 2005, 
Canela et al 2004).  
 
In many cancer types, the expression of telomerase is regained to maintain 
the telomere length (Harley 2008). However some cancer types maintain their 
telomere lengths by using the pathway called alternative lengthening of telomeres 
(ALT) (Bryan et al 1997, Bryan et al 1995). ALT is observed mostly in the 
tumorigenesis of the mesenchymal cell types (Cesare and Reddel 2010). ALT 
pathway employs homolog recombination for the elongation of telomeres 
(Lubland and Blackburn 1993, Bryan et al 1995, Bryan et al 1997). Different 
from the telomerase extended telomeres, the chromosome end of the cells contains 
mostly C-rich strands (Henson et al 2009) and it is proposed that the choice 
towards ALT can be due to the reduction in shelterin complex concentrations 
(Cesare and Reddel 2010). 
 
Recent finding revealed that the epigenetic modifications of the 
subtelomeric repeats, which are highly methylated in normal cells, towards 
hypomethylation increased tumorigenesis and caused telomere elongation (Vera et 
al 2008). Moreover, telomeric repeat containing RNAs (TERRAs) were 
discovered which are transcribed from the telomeric repeats that are normally 
highly methylated. TERRAs are shown to be telomerase inhibitors and have low 
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TERRA transcript concentrations were observed in cancer (Azzalin et al 2007, 
Schoeftner and Blasco 2008, Luke and Lingner 2009, Redon et al 2010). 
 
1.2.2 Telomerase and Stem Cells 
 
Presence of telomerase enzyme was demonstrated in many stem cell types 
including ESC, HSCs and MSCs (Hiyama and Hiyama 2007). Among them, ESCs 
has the highest level of telomerase activity (Brumendov and Balabanov 2006, 
Izadpanah et al 2006). Embryonic stem cells which have limitless potential to 
proliferate, conserved the activity of telomerase enzyme after extensive passaging, 
that is more than 120 (Xie et al 2010). Moreover their differentiation potentials 
were demonstrated to depend on telomerase activity, the concentration of which is 
diminished after differentiation (Armstrong et al 2000). 
 
In HSCs, it has been shown that the telomerase activity was not sufficient 
to maintain telomere length which was further proved by the overexpression 
studies of TERT (Allsopp et al 2001, Allsopp et al 2003). The regenerative 
capacities of the cells were also found to be determined by their niches (Conboy et 
al 2005). HSCs were shown to express more telomerase when they were cultured 
with cytokines in vitro and the enzyme levels were also found to be decreased 
after differentiation and extensive proliferation resulting in aging (Chiu et al 
1996) although it prevents sudden telomere length decrease during regeneration 
which requires rapid proliferation (Allsopp et al 2003). 
 
There are conflicting data in the presence of telomerase enzyme in MSCs. 
According to a study human MSCs in vitro could undergo 50 population 
doublings and have telomerase activity (da Silva and Nardi 2003), in contrast 
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another one indicates that MSCs do not express TERT and have life spans as long 
as somatic cells (Fehrer and Lepperdinger). Moreover another study states that 
without the expression of TERT, MSCs could maintain their telomere lengths 
(Yanada et al 2006). There are suggestions that maintenance of the telomeres in 
MSCs could be by ALT pathway (Serakinci et al 2008). It was demonstrated in 
vitro that when MSCs were isolated from telomerase knockout mice, they lost 
their potential to differentiate and proliferate in contrast with the wild type mice 
(Liu et al 2004). 
 
1.2.3 Telomerase Antagonist GRN163L (Imetelstat) 
 
During transformation of somatic cells into cancer cells telomerase is 
activated which make the cancer cells immortal, for this reason telomerase is a 
good target in the treatment of cancer as normal somatic cells do not express 
telomerase. There are several methods proposed to cure cancer by targeting 
telomerase. One of the approaches depends on the inhibition of telomerase by the 
use of small molecules to promote their efficient binding on the active site of the 
telomerase or telomerase RNA. Another approach employs the disruption of the 
telomeres and prevent the binding of telomerase enzyme. Furthermore there are 
strategies developed to inhibit the expression of the telomerase genes or for gene 
therapy and immunotherapy (Harley 2008). 
 
GRN163L, Imetelstat, is an oligonucleotide that inhibits the activity of 
telomerase. It is a 13-mer oligonucleotide having the sequence of 
TAGGGTTAGACAA containing a N3' P5'-thio-phosphoramidate lipid 
conjugate which is palmitoyl. The palmitoyl serves in the entry of the GRN163L 
into the cell while thio-phosphoramidate provides the backbone a better 
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interaction with proteins and pH stability. When these properties are combined 
GRN163L can easily enter the cell without any requirements to liposomes and 
specifically binds to telomerase RNA forming a double strand that is durable to 
RNAse H degradation (Pongracz and Gryaznov 1999, Gryaznov et al 2001, 
Herbert et al 2005) (Figure 1.2.3.1). 
 
 
 
Figure 1.2.3 1 Action mechanism of GRN163L on telomerase (Harley 2008) 
 
To date in vivo and in vitro properties of GRN163L is widely tested in 
animal models and several cancer cell lines. Dikmen et al (2005) demonstrated the 
effects of GRN163L on A549 luciferase (A549-Luc) cells in vitro, resulting in 
shortened telomeres, loose and less colonies. Moreover they successfully showed 
that immunodeficient mice have less metastasis when the A549-Luc cells were 
previously treated with GRN163L and intraperitoneal administration of GRN163L 
prevented the tumorigenesis of these cells in vivo. Djojosubroto et al (2005) 
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showed the effect of GRN163L on liver cancer cell lines Hep3B and Huh7. These 
cells became more sensitive to chemotherapeutics when previously treated with 
GRN163L and formation of tumors was prevented with intraperitoneal injections 
in nude mice. Similar results were also obtained when breast cancer cells were 
treated with GRN163L both in vitro and in vivo (Gellert et al 2006, Hoechreiter et 
al 2006). Moreover a telomerase independent effect of GRN163L was revealed by 
in vivo and in vitro studies performed with A549-Luc cells. The morphology of 
the cells were becoming round and they were detached from the plate surface 
loosing their adherent properties (Jackson et al 2007). There are also studies 
reporting the successful inhibition of tumorigenesis in glioblastomas, prostate 
cancer, breast cancer, bladder cancer and myelomas (Marian et al 2010, Calin et 
al 2009, Goldblatt et al 2009, Goldblatt et al 2009, Dikmen et al 2008, Shammas 
et al 2008, Gomez-Millan et al 2007, Gellert et al 2006, Hochreiter et al 2006). 
 
GRN163L has ben in clinical trials since 2005 and today there are total of 
7 clinical trials (http://clinicaltrials.gov/ct2/results?term=GRN163L). The aim of 
these trials is to reveal the effects of GRN163L in the treatment of cancer alone or 
as a combinatory treatment in lung cancer, myelomas and breast cancer. Although 
in vivo and in vitro effects of GRN163L is well described in cancer, its effects on 
the quiescent residers of the body, adult stem cells are not known as they also 
maintain telomerase. 
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CHAPTER 2 
 
AIM OF THE STUDY 
 
 
 
 
Mesenchymal stem cells are bone marrow derived stem cells that are able 
to differentiate into adipocytes, osteocytes, chondrocytes, cardiomyocytes and 
they are easy to isolate and manipulate. They can home to the injured tissue and 
have immunomodulatory effects. For these reasons they are important candidates 
in cellular therapies. MSCs can also be frozen to preserve them, and when they 
are thawed they can function apparently normally, thus allowing for future "off-
the-shelf" therapy approaches. However, optimal timing of stem-cell delivery to 
acutely injured tissues or organs can be a major handicap. This issue is of 
paramount importance in cardiovascular medicine (Bartunek et al 2006). The 
assessment of donor MSC functional activity at the cellular level, which is the 
focus of several research groups, is also critically important. There is no available 
data from experimental studies or clinical trials that shows the exact timing of the 
induction of cardiomyocyte differentiation prior to MSC delivery to an injured 
heart or ischemic limb. In the first part of the study, we aimed to demonstrate the 
best timing to induce the differentiation of cardiomyocytes from rat bone marrow 
derived MSCs. 
 
The presence of the telomerase activity in many different kinds of human 
tumors, but not in normal somatic cells has been known for years. Thus, inhibition 
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of telomerase activity is now an attractive tool on targeted cancer therapy. 
Telomerase inhibitor, GRN163L has been shown to have established effects on 
the treatments of the cancers. However this inhibition may lead to side effects 
since germline cells, proliferating stem and progenitor cells also exhibit 
telomerase activity. The effects of telomerase-targeting therapies must be well 
defined on MSCs. Therefore, we aimed to investigate in vitro effects of GRN163L 
on the self-renewal and differentiation processes of MSCs at the second part of 
this thesis. 
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CHAPTER 3 
 
 
 
MATERIALS AND METHODS 
 
3.1 Animals 
 
For all the experiments, adult female 9-week-old, 280–300 g Spraque Dawley 
rats were used. The animals were kept in the animal holding facility of the 
Department of Molecular Biology and Genetics at Bilkent University under 
controlled conditions at 22
o 
C with 12 hour light and 12 hour dark cycles. They 
were provided with unlimited access of food and water. The experimental 
procedures have been approved by Bilkent University Local Ethical Committee 
(BILHADYEK). 
 
3.2 Isolation of the Cells from Rat Bone Marrow 
 
After the rats were sacrificed by cervical dislocation, heterogeneous cell 
population was collected from the femurs and tibias by flushing with a 5 mL 
syringe containing 10% FBS (HyClone, Logan, USA) and 1% 
penicillin/streptomycin solution (Hyclone) in DMEM (HyClone). The mixed 
suspension was then centrifuged at 3000 rpm for 3 min. After the supernatant was 
removed, the cells were washed with 10 mL 1X PBS buffer once. The cells 
suspended in 1X PBS were centrifuged at 2500 rpm for 3 min and then the buffer 
was removed and cells were re-suspended in 10 mL 1X PBS buffer again. The 
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mixture was centrifuged at 2000 rpm for 3 min and then the supernatant was 
removed.10mL 1X PBS buffer was added to the cell pellet and the cells were re-
suspended once more. The cell suspension was centrifuged at 1500 rpm for 3 min 
to get rid of the remaining impurities like fat, connective tissue and hair and then 
after the removal of supernatant, cell pellet was re-suspended in MesenCult 
medium (StemCell Technologies, Vancouver, Canada) with a 20% supplement 
(StemCell Technologies) and a 1% penicillin–streptomycin solution (HyClone) to 
prepare for tissue culturing. 
 
3.3 Culturing of Mesenchymal Stem Cells (MSCs) 
 
Cells were counted with hemocytometer and the cell number was calculated 
according to the below formula 
 
Number of cells in the mixture = number of cells counted x 10
4
 x dilution factor 
 
After the cells were seeded to the plastic culture plates at equal numbers in 
MesenCult medium (StemCell Technologies, Vancouver, Canada) with a 20% 
supplement (StemCell Technologies) and a 1% penicillin–streptomycin solution 
(HyClone), they were cultured in a 5% CO2 incubator at 37°C. The next day, the 
media of the tissue culture plates were changed and the nonadherent cells were 
removed. The media of the cells were changed every 3 days, after washing with 
sterile 1X PBS. The adherent cells on the 14
th
 day of the cell culture were mostly 
MSCs.  
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3.4 Treatment of the MSCs with Telomerase Template Antagonist 
GRN163L (GRN163L) and the Experimental Groups 
 
After 14 days of culture, the cells were trypsinized (HyClone) and transferred 
to culture dishes. One day after the transfer, GRN163L (Geron Co., CA, USA) 
and its mismatch control oligonucleotide were added at a concentration of 1 μM to 
the cell plates. The media were changed every 3 days with the fresh GRN163L 
(hereafter stated as 163L group) and mismatch control oligonucleotide (hereafter 
stated as mismatch group) together with control MSCs with no treatment 
(hereafter stated as control group). 163L and mismatch cultures continued for 1 
week. Finally, GRN163L was removed and MSCs were left for recovery for 1 
week (hereafter stated as 163LR (recovery) group).  
 
3.5 Colony Forming Unit (CFU) Assay 
 
MSCs were washed with 1X PBS and were air dried. They were fixed by ice 
cold methanol (MeOH) for 5 minutes. After fixation MeOH was removed and the 
cells were washed with 1X PBS buffer. The fixed cells were then treated with 
giemsa staining reagent (Carlo Erba) for 5 min. To stop the reaction of giemsa 
staining, tap water was added and the cells were washed with tap water trice. The 
colonies stained in purple were counted under bright field light microscope. 
 
3.6 Total RNA Isolation from Rat MSC  
 
Total RNA from the MSCs were isolated at the 14
th
 day of the cell culture. 
The cells were first washed with 1X PBS buffer twice and were trypsinized at 
37
o
C for 3 min. Trypsinization was ended by the addition of DMEM (Hyclone) 
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containing 10% Fetal Bovine Serum (Hyclone) and 1% penicillin-streptomycin 
solution (Hyclone). Then the cell suspension was centrifuged at 1500 rpm for 5 
min. After centrifugation the media was removed and the cell pellet was washed 
with 1X PBS buffer and centrifuged again at 1500 rpm for 5 min. Finally, the 
supernatant was removed and the total mRNA was isolated from the cell pellet by 
using RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. 
 
3.7  cDNA Synthesis 
 
The cDNAs were synthesized from the total RNA samples by using 
DyNAmo cDNA Synthesis Kit (Finnzymes, Finland) according to the 
manufacturer's protocol. 2 µg RNA was mixed with DEPC treated ddH2O to a 
total volume of 10,5 µl and 1,5 µl of oligo(dT) primer was added and the mixture 
was centrifuged for 3 sec. The samples were incubated at 65°C for 5 minutes and 
then chilled on ice for 3 minutes. Then 15 µl of 2X RT buffer including dNTP 
mix and 10 mM MgCl2  and 3 µl of M-MuLV RT RNase H
+
 enzyme was added to 
the mixture, after a 3 sec centrifugation they were incubated at 25ºC for 10 min, 
45ºC for 45 min, and 85ºC for 5 minutes, respectively. 
 
3.8 Primer Design 
 
Primer designs were performed by using the combination of Primer exe, 
Primer Blast (NCBI) and Primer Premier. The specificity of the primers and 
product sizes they would amplify were checked via Ensemble and NCBI 
databases publicly available through the internet. Primers for all the genes 
amplified were listed in Table 3.9. 
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Table 3.8 List of Primers and the product sizes they amplify 
 
 
Name of the 
gene 
Sequences of Forward (F) and Reverse (R) 
Primers 
Size (bp) 
TERT 
(F) 5’- GCTACGCCATCCTGAAGGTC-3’ 
(R) 5’-GGTAGCAGAGCCAACGTGTG-3’ 
99 
CYCLINB1 
(F) 5’- TCGATGTGGAGCAGCATACT-3’ 
(R) 5’- GTCCATTCACCGTTGTCAAG-3’ 
142 
CDK4 
(F) 5’- GAAGACGACTGGCCTCGAGA-3’ 
(R) 5’- ACTGCGCTCCAGATTCCTCC-3’ 
109 
CDK6 
(F) 5’- TTGTGACAGACATCGACGAG-3’ 
(R) 5’- GACAGGTGAGAATGCAGGTT-3’ 
151 
CDK2 
(F) 5’- TGACCAACTCTTCCGGATCT-3’ 
(R) 5’- ATAACAAGCTCCGTCCGTCT-3’ 
164 
CDK1 
(F) 5’- GTTGACATCTGGAGCATAGG-3’ 
(R) 5’- CTCTACTTCTGGCCACACTT-3’ 
144 
CYCLINA2 
(F) 5’- CTGCCTTCCACTTAGCTCTC-3’ 
(R) 5’- GAGGTAGGTCTGGTGAAGGT-3’ 
125 
RB 
(F) 5’ – TTGAAAGAAGAGGCACTCCC -3’ 
(R) 5’ – CGCTACCTTAAATACCGCCT -3’ 
116 
P53 
(F) 5’- GTTCCGAGAGCTGAATGAGG -3’ 
(R) 5’- AGACTGGCCCTTCTTGGTCT -3’ 
109 
Bmi-1 
(F) 5’- ATGTGTGTCCTGTGTGGAGG-3’ 
(R) 5’-AGCCATTGGCAGCATCTGCT-3’ 
281 
P21 
(F) 5’-ATGTCCGATCCTGGTGATGTC-3’ 
(R) 5’- CGGCTCAACTGCTCACTGTC- 3’ 
92 
Cdc25a 
(F) 5’-AGTGAAGAGAGCAGACCGAT-3’ 
(R) 5’-GGAGAGAGACTGGTGTGGAA-3’ 
126 
P16INK4a 
(F) 5’- CTTCACCAAACGCCCCGAACA-3’ 
(R) 5’- CGGGAGAGGGTGGTGGGGTC-3’ 
132 
P19ARF 
(F) 5’- GCAGAGCATGGGTCGCAGGTTC-3’ 
(R)5’- CGGGAGAGGGTGGTGGGGTC-3’ 
295 
CYCLIN D1 
(F) 5’- AATGCCAGAGGCGGATGAGA- 3’ 
(R) 5’- GCTTGTGCGGTAGCAGGAGA- 3’ 
189 
CYCLIN E 
(F) 5’- TTACTGATGGTGCTTGCTCC -3’ 
(R) 5’- GTCGTTGACGTAGGCCACTT - 3’ 
136 
Cyclophilin 
(F) 5'-GGGAAGGTGAAAGAAGGCAT-3' 
(R) 5'-GAGAGCAGAGATTACAGGGT-3' 
211 
Cardiac 
Troponin I 
(F) 5’ – GCGAAGCAGGAGATGGAG – 3’ 
(R) 5’ – TGCCACGCAGGTCATAGA – 3’ 
250 
Alpha 
Skeletal Actin 
(F) 5’ - ATCTCACGTTCAGCTGTGGTCA -3’ 
(R) 5’ - ACCACCGGCATCGTGTTGGAT - 3’ 
182 
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α-Sarcomeric 
Actin 
(F) 5’ – CCAGGCACTGTGGAAAGG – 3’ 
(R) 5’ – CACGATGGATGGGAAGAC -3’ 
286 
MEF2D 
(F) 5’ – TGGGAATGGCTATGTCAGTG -3’ 
(R) 5’ – CTGGTAATCTGTGTTGTAGG – 3’ 
351 
GAPDH 
(F) 5’- CCTCCTCATTGACCTCAACTAC - 3’ 
(R) 5’ – CATGGTGGTGAAGACGCCAG – 3’ 
219 
CD 90 
(F) 5’- CCAGTCATCAGCATCACTCT-3’ 
(R) 5’- AGCTTGTCTCTGATCACATT- 3’ 
374 
CD 34 
(F) 5’- TGTCTGCTCCTTGAATCT -3’ 
(R) 5’- CCTGTGGGACTCCAACT- 3’ 
281 
CD 71 
(F) 5’- ATGGTTCGTACAGCAGCAGA-3’ 
(R) 5’- CGAGCAGAATACAGCCATTG-3’ 
182 
CD 29 
(F) 5’-ACTTCAGACTTCCGCATTGG -3’ 
(R) 5’- GCTGCTGACCAACAAGTTCA-3’ 
190 
CD 45 
(F) 5’- ATGTTATTGGGAGGGTGCAA-3’ 
(R) 5’- AAAATGTAACGCGCTTCAGG-3’ 
175 
 
3.9 RT-PCR 
 
cDNA amplification for cardiac troponin I (cTnI), α-sarcomeric actin, 
MEF2D, GAPDH, CD90, CD71, CD45, CD34, CD29 and cyclophilin were 
performed by using DyNAzyme II (Finnzymes). PCR conditions for these genes 
are listed in Table 3.10. 
 
Table 3.9  RT-PCR Conditions 
 
Genes 
Initial 
denaturation 
Denaturation Annealing Extension Cycles 
Final 
extension 
CD 90 95°C, 5 min 94°C, 30 sec 
55°C, 30 
sec 
72°C, 30 
sec 
30 72°C, 5 min 
CD 34 95°C, 5 min 94°C, 30 sec 
55°C, 30 
sec 
72°C, 30 
sec 
30 72°C, 5 min 
CD 71 95°C, 5 min 94°C, 45 sec 
66°C, 60 
sec 
72°C, 45 
sec 
35 72°C, 5 min 
CD 29 95°C , 5 min 94°C, 30 sec 
60°C, 30 
sec 
72°C, 30 
sec 
23 72°C, 5 min 
CD 45 95°C, 5 min 94°C, 30 sec 60°C, 30 72°C, 30 23 72°C, 5 min 
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sec sec 
Troponin 
95°C, 5 min 94°C, 45 sec 
65°C, 30 
sec 
72°C, 40 
sec 
33 72°C, 5 min 
α-Sarcomeric 
actin 
95°C, 10 min 94°C, 45 sec 
57°C, 60 
sec 
72°C, 60 
sec 
35 72°C, 10 min 
MEF2D 
95°C, 10 min 94°C, 30 sec 
57°C, 60 
sec 
72°C, 50 
sec 
33 72°C, 5 min 
GAPDH 
95°C , 5 min 94°C, 30 sec 
59°C, 30 
sec 
72°C, 30 
sec 
23 72°C, 5 min 
Cyclophilin 
95°C , 5 min 94°C, 30 sec 
55°C, 30 
sec 
72°C, 30 
sec 
23 72°C, 5 min 
 
3.10 Agarose Gel Electrophoresis 
 
1% agarose gel was prepared with 1X TAE Buffer and 1 mg/ml ethidium 
bromide solution. Samples were prepared by addition of 4 μl 6X Agarose Gel 
Loading Dye to 25 μl of PCR product and loaded to the agarose gel at equal 
volumes. The gel was run at 85V for 45 minutes and visualized under 
transilluminator (Gel-Doc Bio-Rad, USA or Vilber Lourmat, France). 
Chemicapture (Vilber Lourmat, France) software was used to take photographs of 
the gels. The Gene Ruler DNA Ladder Mix (Fermentas, #SM0331) was used as a 
marker and 5 µl was loaded to each gel. 
 
3.11 Semiquantitative Analysis of RT-PCR 
 
Semiquantitative analysis was performed by using Bio1D (Vilber Lourmat, 
France) after the gel photos were taken. 
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3.12 Q-RT-PCR 
 
DyNamo HS SybrGreen qPCR kit was used at all reactions at a reaction 
volume of 20 μl containing 10 μl DyNamo HS SybrGreen Taq mix 1 μl 10 pmol 
forward and 1 μl 10 pmol reverse primers, 7 μl ddH2O and 1 μl cDNA. The 
primers used for Q- RT-PCR are shown in Table 1. Cyclophilin was used as a 
housekeeping reference gene. Before performing Q- RT-PCR reactions for 
experimental samples, the amplification efficiencies of all primers were calculated 
using a standard dilution series. Fold changes in the expression of the genes were 
estimated based on the comparative 2
-ΔΔCt
 method, using the normal MSCs as 
calibrator. The Q-RT-PCR amplification protocols for all investigated genes were 
listed in Table 3.13. Each protocol was followed by a melt curve to check the 
purity of the product amplified. 
 
Table 3.12 Q-RT-PCR conditions 
 
 Initial 
denaturation 
Denaturation Annealing Extension Cycles 
Final 
extension 
TERT 95°C, 10 min 94°C, 30 sec 60°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
CYCLINB1 95°C, 10 min 94°C, 30 sec 55°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
CDK4 95°C, 10 min 94°C, 30 sec 60°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
CDK6 95°C , 10 min 94°C, 30 sec 55°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
CDK2 95°C, 10 min 94°C, 30 sec 55°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
CDK1 95°C, 10 min 94°C, 30 sec 55°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
CYCLINA2 95°C, 10 min 94°C, 30 sec 60°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
RB 95°C , 10 min 94°C, 30 sec 55°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
P53 95°C, 10 min 94°C, 30 sec 65°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
Bmi-1 95°C, 10 min 94°C, 30 sec 60°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
P21 95°C, 10 min 94°C, 30 sec 55°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
Cdc25a 95°C , 10 min 94°C, 30 sec 59°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
P16INK4a 95°C, 10 min 94°C, 30 sec 62°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
P19ARF 95°C, 10 min 94°C, 30 sec 68°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
CYCLIN D1 95°C, 10 min 94°C, 30 sec 65°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
CYCLIN E 95°C , 10 min 94°C, 30 sec 59°C, 30 sec 72°C, 30 sec 45 72°C, 10 min 
Cyclophilin 95°C, 10 min 94°C, 30 sec 55°C, 30 sec 72°C, 30 sec 35 72°C, 10 min 
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3.13 Telomeric Repeat Amplification Protocol (TRAP) 
 
1x10
6
 MSCs were collected by trypsinization and a TRAP-eze Telomerase 
Detection Kit (Millipore, MA, USA) was used to detect telomerase activity. A 
nondenaturing polyacrylamide gel based assay was performed for visualization of 
the telomeric repeats after PCR, according to the manufacturer’s protocol. Gels 
were stained with SYBR Green I (Sigma, MO, USA) at 1:10000 dilution in TAE 
and visualized with Vilber Lourmat ChemiCapture (Marne-La-Vallée Cedex, 
France). 
 
3.14 Total Protein Isolation from MSCs 
 
MSCs were scraped from the cell culture plates in 1X PBS after washing 
with 1X PBS twice. The cells were transferred to a falcon tube and centrifuged at 
1500 rpm for 5 min at 4°C and the precipitate was treated with a lysis buffer for 
30 min on ice, by vortexing with 5 min intervals for 30 sec. Then the lysate was 
centrifugated for 20 min at 13000 rpm at 4°C. The supernatants were transferred 
to a new eppendorf tube and the protein concentrations of supernatants were 
determined with Bradford protein assay as described by Bradford (1976). 
3.15 Western Blotting 
3.15.1   Sodium Dodecyl Sulphate – Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
 
The denaturing gel was prepared with 4-6% stacking gel and 8-10% 
separating gel, the former pore size was used for the proteins bigger than 45 kDa 
and the latter one was used for the protein smaller than that size. The 30 μg of 
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protein was mixed with 10 μl of 2% cracking buffer which contains 5% b-
mercaptoethanol and heated at 95°C for 5 min. After denaturation step they were 
held on ice for 5 min. After the gel was soaked into the 1X running buffer that 
completely covers the wells and the electrodes, the proteins were loaded to the gel 
with 5 μl of the prestained protein molecular weight marker (SM0671, MBI 
Fermentas, Ontario, Canada) and run at 60V with 20V increments after every 45 
min. The gel was run until the prestained marker was separated enough to detect 
the required range of kDa. 
 
3.15.2 Semi-dry transfer of proteins to a PVDF membrane 
 
After the gel was run and removed from the gel apparatus the stacking part 
was cut off and separating part was soaked in semi-dry transfer buffer at most 5 
min. Beforehand, PVDF membrane and 4 wattmann papers were cut to be at the 
same size with the separating part of the gel. PVDF membrane was activated by 
soaking with MeOH for 30 sec. The excess MeOH was removed by washing with 
ddH2O for 2 min by vigorous shaking. Then it was soaked in semi-dry transfer 
buffer at the same time with the gel in different containers. Wattmann papers were 
soaked in semi-dry transfer buffer for 1 min. The transfer sandwich was prepared 
at the order of; 2 wattmann papers, membrane, gel, 2 wattmann papers. At the first 
3 steps and last step the air bubbles were removed. The transfer was performed at 
a current to be 3,5 mA/cm
2
 for 45 min. After the transfer is completed the gel was 
stained with coomassiee brilliant blue for 30 min and destained overnight to check 
complete transfer at the required range of kDa. 
 
3.15.3 Immunological detection of Immobilized Proteins 
 
After the transfer membrane was equilibrated in 1X TBS buffer for 5 min 
and then blocked with a blocking solution in 1X TBS-(0.1%)T at least for 1h at 
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RT on an orbital shaker (Thermolyne). The membrane is then cut by two with a 
sterile blade two perform the detection of housekeeping protein at the same 
blotting. Primary antibodies were added at the concentration of 1:200 for Bmi-1, 
TERT, Cdc25a, Cyclin A, Cdk4, Cyclin D1, Cyclin E, 1:1000 for Cdk1, Cdk2, 
Cyclin B1, p53, 1:2000 for Cdk6, α-Tubulin and left o/n at 4oC. The following 
day the membrane was washed with 1X TBS-T four times at intervals indicated; 5  
min, 10 min, 10 min, 5 min. They were incubated with the related horseradish 
peroxidase linked secondary antibody (anti-rabbit IgG HRP (Cell Signaling 
Technology, USA) 1:2500 and anti-mouse IgG HRP (Santa Cruz, CA, USA) 
1:2000) in blocking solution for 1 h at RT on an orbital shaker. After 1 h 
membranes were washed again as indicated previously. Finally, Super Signal 
West Femto Maximum Sensitivity Substrate (Thermo Scientific, IL, USA) was 
applied to the membrane for 5 min and after draining the excess solution covered 
with stretch film on glass and placed in an X-ray film cassette and developed. 
(Anti-Bmi-1, TERT, Cdc25a, Cyclin A, Cdk4, Cyclin D1, and Cyclin E 
antibodies were purchased from Santa Cruz (Santa Cruz, CA, USA). Anti-Cdk1, 
Cdk2, Cyclin B1 and p53 antibodies were purchased from Cell Signaling 
Technology (Danvers, MA, USA). Anti- α-Tubulin antibody was purchased from 
Calbiochem (Darmstadt, Germany). 
 
3.16 Immunocytochemistry 
 
Cells in the cover slips were fixed for 7 min in ice cold MeOH after 
removing the medium and washing with 1X PBS. The cells were then treated with 
3% H2O2 to quench endogenous peroxidase activity. After washing 3 times with 
PBS, After washing three times with 1X PBS, the cells were left in blocking 
solution which contains 1% BSA and 0.5% Tween20 in 1XPBS, for 30 min at RT. 
Primary antibodies of CD90 and CD34 (Chemicon, Temecula, Canada) were 
applied at a concentration of 1:500 dilution in blocking solution and kept at 4-8ºC 
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overnight. After washing 3 times with 1X PBS, cells were incubated for 15 min 
with universal biotinylated link (DakoCytomation, Glostrup, Denmark) then 
biotinylated link is washed and the cells were treated with streptavidinHRP 
(DakoCytomation) for 15 min at RT. After washing with 1X PBS, color 
developments were achieved by incubation for 5 min with liquid DAB+ 
(DakoCytomation). Excess was washed by ddH2O and counterstaining was 
performed with hematoxylin by staining for 30sec at RT then the cells on 
coverslips were mounted with mounting medium (DakoCytomation). 
 
3.17 Differentiation of MSCs 
3.17.1  Differentiation of MSCs into Cardiomyocytes 
 
 
Two different time points were used for the cardiomyocyte differentiation of 
MSCs. In the first group, differentiation was induced on day 9 of the culture 
(hereafter stated as the 9th day) and in the second group, differentiation was 
induced on day 14 (hereafter stated as the 14th day). The induction of 
cardiomyocyte differentiation was performed by incubating cells with 10mmol/L 
5-azacytidine (Sigma, Steinheim, Germany) for 24 h. The cells were washed and 
expanded for another 14 days with low-glucose DMEM (Invitrogen) containing 
20% FBS (HyClone), and 1% penicillin-streptomycin (HyClone). 
 
3.17.2 Differentiation of MSCs into Adipocytes 
 
 
An adipogenic induction medium was prepared by freshly adding 1 μM 
dexamethasone (Sigma), 10 μg/ml insulin (Sigma), 100 μM indomethacin (Sigma) 
and 0.5 mM IBMX to LG-DMEM (HyClone), containing 1% penicillin-
streptomycin (HyClone) and 10% FBS (HyClone). The MSCs were cultured for 
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21 days, changing the medium every 2 days with freshly prepared medium. After 
21 days the cells were fixed with 4% paraformaldehyde for 30 min. Fixative was 
washed with 1X PBS twice and 3 times with ddH2O and the cells were covered 
with Oil Red O Solution (Sigma, Steinheim, Germany) and incubated for 50 min 
at RT. The cells then were washed with ddH2O 3 times and counterstained with 
hematoxylin for 30 sec at RT. The reaction was ended by washing with tap water 
3 times. The cells were kept in ddH2O to prevent from drying for observation. 
 
3.17.3 Differentiation of MSCs into Osteocytes 
 
 
An osteogenic induction medium was prepared by freshly adding 0.1 μM 
dexamethasone (Sigma), 0.2 mM ascorbic acid 2-phosphate (Sigma) and 10 mM 
glycerol-2- phosphate (Sigma) to LG-DMEM (HyClone), containing 1% 
penicillin-streptomycin (HyClone) and 10% FBS (HyClone). The MSCs were 
cultured for 21 days, changing the medium every 2 days by freshly prepared 
medium. After 21 days the cells were fixed with 70% ethanol for 1h at RT and 
rinsed twice with ddH2O and stained with Alizarin Red S (Sigma) for 30 min at 
RT. The cells were washed with ddH2O for 3 times and kept in ddH2O to prevent 
from drying for observation. 
 
3.18 Intracellular Ca+2 measurement 
 
Cells were grown on round cover slips in 6-well plates and loaded with fura-
2 AM at RT for 50 min. Cells were then washed before the experiments with 
Hepes-buffered physiologic NaCl bathing solution containing 1.2 mmol/L Ca
+2
 
and 1 mmol/L Mg
+2
. Cells were challenged either with caffeine to stimulate 
ryanodine receptors or with ATP to stimulate P2Y purinergic receptors. In 
addition, high-KCl bathing solutions were applied and intracellular calcium 
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concentrations were monitored to see whether depolarization could induce any 
intracellular Ca
+2 
transients. Cover slips were fixed to a Teflon chamber and 
mounted on an inverted fluorescent microscope (Nikon TE-300, Japan). 
Fluorescence ratios were obtained by exciting cells at 340 and 380 nm with a  
microscope-based spectrofluorimeter with a temporal resolution of one ratio every 
0.5 s. Emission signals were collected at 510 nm with an IC-300 ICCD 
(intensified charge-coupled device) camera with Delta Ram, (Photon Technology 
International, USA). Data was collected and analyzed by Image Master software 
(Photon Technology International).  
 
3.19 Statistical Analysis 
 
All data are expressed as means ± SD. Data were analyzed by performing a 
paired t- test using Minitab Statistical Software ® (State College, Pennsylvania, 
USA). A value of p<0.05 was considered to be statistically significant. 
 
3.20 Buffers and Solutions 
 
The preparation of the buffers and solutions are listed in Appendix A 
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CHAPTER 4 
 
RESULTS 
 
 
4.1   Timing of Induction of Cardiomyocyte Differentiation for 
in vitro Cultured Mesenchymal Stem Cells 
 
According to the World Health Organization (WHO) 2008 health report, 
ischemic heart diseases are the number one life threatening diseases followed by 
several types of cancers. Moreover, this ranking is expected to be the same in the 
fore-coming 20 years.  
 
Mesenchymal stem cells (MSCs) have important features for cellular 
therapies as they can differentiate into different lineages like cartilage, bone, fat 
and muscle. They can also differentiate into cardiomyocytes which is very well 
established in the literature together with its cellular applications in murine 
animals (Friedenstein et al 1970, da Silva et al 2008). However, for clinical 
applications the timing of the cellular therapy can be life saving. 
 
According to our established MSC culturing protocol, it takes 14 days to 
generate fully mature MSCs. According to our previous studies, also on the 9
th
 
day of the culture there are, although less, mature MSCs in the cell culture plate 
(Terzioğlu E, 2006). However, their differentiation capacities into any lineages 
were not checked as early as day 9. We hypothesized that if the cells could 
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differentiate into cardiomyocytes as early as day 9, it would save 5 days for 
cellular therapies. 
 
To determine the timing of induction into cardiomyoctes we used primary 
bone marrow of adult female rats and all the experiments were performed on both 
9
th
 and 14
th
 days of in vitro cell culture. All the experiments were performed with 
3 different sets of animals for significancy. 
 
4.1.1 Characterization of Mesenchymal Stem Cells (MSCs) on 9th 
and 14
th
 Days of Cell Culture 
 
 
We first investigated the characteristics of MSCs on the 9
th
 and 14
th
 days 
of the culture by their CD90 expressions and CFU-F activities. We performed 
CD90 immunocytochemistry analysis on day 9 and 14. Both on the 9
th
 and 14
th
 
day of the culture, the cells were positive for CD90 (Figure 4.1.1.1A and 
4.1.1.2A). 
 
Another distinguishing feature of MSCs is their colony forming capacity. 
Giemsa staining is performed to determine their CFU-F. It was observed that both 
on 9
th
 and 14
th
 days the cells were forming colonies (Figure 4.1.1.1C and 
4.1.1.2C). When we omitted primary antibody as negative control, we did not 
observe any staining (Figure 4.1.1.1B and 4.1.1.2B). 
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Figure 4.1.1 1 Characterization of MSCs on the 9
th
 day of cell culture 
(magnification 20x) 
  
 
 
Figure 4.1.1 2 Characterization of MSCs on the 14
th
 day of cell culture 
(magnification 20x) 
 
 
 
Cardiomyocytes contract in synchrony to enable the contraction of the 
heart. For this purpose a fully differentiated cardiomyocyte must respond to 
depolarizations and must enable the spreading of action potentials which is 
performed by the increase in cytoplasmic Ca
+2
 levels. Therefore, we examined the 
levels of Ca
+2
 by using fura-2AM staining. 
 
Before differentiation of MSCs into cardiomyocytes, their depolarization 
properties were determined as a negative control. For this purpose, cytoplasmic 
Ca
+2
 levels of MSCs in response to extracellular KCl and caffeine were examined. 
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Upon treatment with 45-60 mmol/L extracellular KCl and 10 mmol/L caffeine, at 
neither 9
th
 day nor 14
th
 day of cell culture increase at cytosolic Ca
+2 
levels were 
observed (Figure 4.1.1.3 and 4.1.1.4 respectively). On the other hand, they 
responded to (0.5x10
-4
 M) extracellular ATP application with a clear Ca
 +2
 
transient (Figure 4.1.1.3 and 4.1.1.4 respectively). 
 
 
 
Figure 4.1.1 3 Cytoplasmic calcium levels of MSCs in response to KCl and 
caffeine measured with fura-2AM on the 9
th
 day of the culture 
 
 
 
 
 
 
Figure 4.1.1 4 Cytoplasmic calcium levels of MSCs in response to caffeine 
measured with fura-2AM on the 14
th
 day of the culture 
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Immunocytochemistry and CFU-F results confirmed that the cells that 
were obtained both on the 9
th
 and 14
th
 days of the culture were MSCs and further 
analysis of intracellular Ca
+2
 levels revealed that the cells were undifferentiated as 
they did not respond to depolarization. 
 
4.1.2 Validation of the Cardiomyocyte Differentiation 
 
As indicated before, cardiomyocytes contract in synchrony to enable the 
contraction of the heart. For this purpose a fully differentiated cardiomyocyte 
must respond to depolarizations and must enable the spreading of action potentials 
which is performed by the increase in cytoplasmic Ca
+2
 levels.  
 
MSCs from the 9
th
 and 14
th
 days of the culture were treated with 5-
Azacytidine to induce cardiomyocyte differentiation. Fourteen days after this 
treatment, the cells were checked for their responses upon 45-60 mmol/L KCl and 
10 mmol/L caffeine incubation. We checked their cytosolic Ca
+2
 levels with fura-
2AM to validate their contractility. It has been observed that when the cells were 
treated with 10 mmol/L caffeine neither the cells from day 9 nor day 14 showed 
increase in cytoplasmic Ca
+2
 levels (4.1.2.1A and 4.1.2.2A respectively). 
However, when the cells were treated with 45-60 mmol/L extracellular KCl, an 
increase at cytoplasmic Ca
+2
 levels were observed at both time points of induction 
(Figure 4.1.2.1B and 4.1.2.2B respectively).  
 
As caffeine increases cytosolic Ca
+2 
levels via ryanodine receptors, it is 
possible that the functional receptors have not been formed yet. The responses to 
KCl, however show apparently that the voltage gated Ca
+2
 channels became active 
after induction of cardiomyocytes both on 9
th
 and 14
th
 days of cell culture. All 
cells responded to ATP (0.5x10
-4
 M) application with a sudden cytoplasmic Ca
+2
 
increase. 
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Figure 4.1.2 1 Cytoplasmic calcium levels of cardiomyocytes, differentiated from 
the MSCs on 9
th
 day of the culture, in response to KCl and caffeine measured with 
fura-2AM. 
 
 
 
 
 
 
 
Figure 4.1.2 2 Cytoplasmic calcium levels of cardiomyocytes, differentiated from 
the MSCs on 14
th
 day of the culture, in response to KCl and caffeine measured 
with fura-2AM. 
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CD90 immunocytochemistry assay was also performed after induction of 
differentiation to check whether there were undifferentiated MSCs. After 
cardiomyocyte differentiation, the cells which were induced to differentiate on 9
th
 
day and 14
th
 day of the culture found to be negative for CD90 protein expression 
(Figure 4.1.2 3A and Figure 4.1.2 3B).  
 
 
 
Figure 4.1.2 3 CD90 immunocytochemistry after induction of differentiation (A) 
on 9
th
 day (B) on 14
th
 day (magnification 20x) 
 
 
Differentiation of MSCs into cardiomyocytes was further investigated by 
analyzing the mRNA expressions of cardiac-specific early markers such as 
troponin I, α-sarcomeric actin and MEF2D. The expressions of these marker 
genes were semiquantitatively analyzed by RT-PCR relative to GAPDH 
expressions by using cells grown in control media as calibrator. The expression of 
these genes were found to increase slightly at both induction time points and 
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expressions of troponin I (p = 0.04) and α-sarcomeric actin (p = 0.01) were 
significant at the cells induced to differentiate on 9
th
 day of the culture (Figure 
4.1.2 4). 
 
 
 
Figure 4.1.2 4 Expression profile of cardiac-specific markers in 5-azacytidine-
treated MSCs on the (A) 9
th
 and (B) 14
th
 day of culture (* indicates p<0.05). 
 
 
4.2 Effects of GRN163L on MSCs 
 
GRN163L is a telomerase antagonist which is used in cancer treatment. It 
reduces the telomeric length by inhibiting telomerase activity and moreover it 
reduces the attachment of the cells on the plate surface which is referred as the 
rounding effect. In consequent treatment the combination of these effects kills the 
cancer cells (Gellert et al 2006, Dikmen et al 2005, Wang et al 2004). 
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Stem cells also have telomerase activity to maintain their telomere length 
which is kept stable to provide longevity to these cells. MSCs, one of the adult 
stem cells in the body, are also shown to have telomerase activity at early 
passages in vitro (Sethe et al 2006). The effect of telomerase inhibition on adult 
stem cells is known neither in vitro nor in vivo.  
 
To determine the effect of GRN163L on MSCs, BM from 3 sets of adult 
female rats were used and all the experiments were performed 3 times for 
significancy. Four experimental groups were involved as previously described in 
section 3.4. Normal MSCs which received no treatment, hereafter stated as control 
group; MSCs treated with the mismatch oligonucleotide of GRN163L, hereafter 
stated as mismatch group; normal MSCs treated with 1 µM GRN163L for 1 week, 
hereafter stated as 163L group; normal MSCs treated with 1 µM GRN163L for 1 
week and left for recovery for 1 week hereafter stated as 163LR (recovery) group. 
 
4.2.1 Phenotypic Effects of GRN163L on MSCs 
 
GRN163L is known to affect the phenotype of the cells by causing a 
rounding effect, detaching the cells from culture surface, at first this phenotypic 
effect of GRN163L on MSCs was examined. After 14
th
 day of the culture when 
the MSCs were mature, the cells were trypsinized and counted to be 1x10
6
 cells 
and reseeded to 6-well plates. GRN163L was added into two wells at the same 
time with seeding at a concentration of 1 µM. As the oligonucleotide loses its 
effect in 3 days in vitro, fresh oligonucleotide was added into the medium every 3 
days. While changing the media of GRN163L treated samples, extensive care was 
taken as the cells were floating. In order to not to loose cells the media were 
centrifuged and the cells were added to the culture plate again. 
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During the treatment, the rounding effect was observed at the 163L treated 
group, the cells detached from the plate surface and the cells ceased growing 
(Figure 4.2.1 1 C). MSCs in the control and mismatch treated group, were 
growing normally and had fibroblastic phenotypes as expected (Figure 4.2.1 1 A 
and B). in the treatment group, during treatment with GRN163L, rounding effect 
and cessation of growth were observed, however it was noticed that after the cells 
left for recovery (163LR group), so that the drug was no more administered, the 
cells reattach to plate surface and start dividing again (Figure 4.2.1 1 D). 
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Figure 4.2.1 1 Effect of GRN163L (a-d: phenotypic effects, A. untreated MSCs 
(control), B. mismatch oligonucleotide treated MSCs (mismatch) C. 1µM 
GRN163L treated MSCs (163L) D. MSCs treated with GRN163L and then left 
for recovery (163LR) E. expression of CD markers of MSCs. 
 
 
As GRN163L ceased the growth of the cells and detached them from the 
plate culture in vitro, it was important to check the surface markers to assure that 
the cells were still MSCs. CD90, CD29 and CD71 which are the important CD 
markers of MSCs were checked together with the hematopoetic markers CD34 
and CD45 by RT-PCR. All the groups were expressing the positive markers 
CD90, CD29 and CD71 and no mRNA expression of the negative markers CD34 
and CD45 were observed as expected (Figure 4.2.1 1 E). The results showed that 
although the cells were treated with 163L they kept their MSC markers both at the 
time of treatment and after they recovered. 
 
 56 
4.2.2 Effects of GRN163L on the Differentiation capacities of 
MSCs 
 
 One of the most important properties of MSCs is their differentiation 
capacities into different lineages therefore, adipogenic and osteogenic 
differentiation capacities of the MSCs were checked after treatment with 163L in 
vitro. As the cells couldn’t attach to plate surface during 163L treatment they 
couldn’t be induced to differentiate. However it is important to keep their ability 
to differentiate after recovering from 163L treatment. For this purpose 163LR 
group was employed together with the control group in differentiation protocols.  
 
 To determine adipogenic differentiation the cells were induced in 
adipogenic medium for 21 days and then stained with Oil Red O staining to 
visualize the lipid droplets. It was observed that in adipogenic differentiation there 
were lipid droplets in control and in 163LR group (Figure 4.2.2 1 A and C) 
whereas no droplets were seen at the negative control samples (Figure 4.2.2 1 B 
and D). Osteogenic differentiation was performed by incubating the control MSCs 
and 163LR group in osteogenic induction media and the calcium deposits were 
determined by Alizarin Red staining. At both control and 163LR group the 
calcium deposits were observable after 21 days of induction (Figure 4.2.2 2 A and 
C) and no staining was observed at negative controls (Figure 4.2.2 2 B and D). 
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Figure 4.2.2 1 Adipogenic differentiation of MSCs determined by Oil Red O 
staining 
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Figure 4.2.2 2 Osteogenic differentiation of MSCs determined by Alizarin Red 
staining 
 
 
4.2.3 Effects of GRN163L on Telomerase of MSCs 
 
 The telomerase enzyme activity was checked by TRAP assay. In this assay 
A549 non small cell lung cancer cell line was used as a positive control as it was 
previously shown to have telomerase activity (Dikmen et al 2005). Heat treated 
samples and lysis buffer were negative controls. 
 
 TRAP assay results revealed that MSCs have telomerase activity and when 
they were treated with 163L their telomerase activity was inhibited as no 
telomeric ladder was observed (Figure 4.2.3 1). However such an inhibition was 
not observed at the mismatch treated group. Moreover after recovery, at 163LR 
group, the telomerase activity was regained.  
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Figure 4.2.3 1 TRAP assay of MSCs to determine telomerase activity A. normal 
samples B. heat inactivated samples 
 
 
4.2.4 Effects of GRN163L on the Cell Cycle of MSCs 
 
 As mentioned before, it was observed that the cells ceased growing during 
treatment with GRN163L. Cell cycle genes were investigated both at mRNA and 
protein level in order to reveal which genes were affected. To investigate the 
mRNA expressions of the cell cycle genes q-RT-PCR was employed by using 
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SyberGreen I detection system. For each primer a run with dilution series of ½, 
involving 6 dilution samples, was performed and amplification efficiencies were 
determined by plotting standard curves according to the slope of the trend line. 
The efficiency values used are listed in (Table 4.2.4). 
 
 
Table 4.2.4 Efficiency values for the primers used in q-RT-PCR. 
 
Name of the gene Efficiency 
TERT 1.78 
CYCLINB1 1.88 
CDK4 1.78 
CDK6 1.94 
CDK2 1.94 
CDK1 1.94 
CYCLINA2 1.74 
RB 2.0 
P53 1.94 
Bmi-1 1.99 
P21 1.72 
Cdc25a 1.94 
P16INK4a 1.90 
P19ARF 1.81 
CYCLIN D1 1.78 
CYCLIN E 1.78 
Cyclophilin 1.94 
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The mRNA expressions of all the genes listed were investigated by using 
control MSC sample as a calibrator. Gene expressions of untreated control MSCs, 
163L, 163LR and mismatch groups were examined. After the analysis of q-RT-
PCR results, mRNA expressions of all the genes were observed to decrease when 
treated with 163L, whereas among them the decrease at cdc25A, cyclinB1, 
cyclinD1, cyclinE, cdk6, p21, p19 and Bmi-1  were significant with p<0.05 
(Figure 4.2.4 1). The expression levels of all the genes were getting back to the 
same level or slightly higher except cyclinB1 and RB that have slightly lower 
expressions. When the mismatch treated group is considered it was observed that 
all the expressions were higher than 163L treated group. 
 
 
 
Figure 4.2.4 1 mRNA expressions of cell cycle genes in MSCs from control, 
163L, 163LR and mismatch groups, determined with Q-RT-PCR. * indicates 
p<0.05. 
 
  
 
The protein expressions were checked with Western blotting. The protein 
amounts of cdk2, cdk4, cyclinD1 were found to decrease at 163L treated groups 
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when compared with control and restored to the same level with control when 
163L is removed and cells were left for recovery (Figure 4.2.4 2). The expression 
of cdc25A were absent at control and 163L groups but increases after removal of 
163L while other proteins tested showed a similar pattern with tubulin alpha, 
which is used as a loading control 
 
The experiments were performed with 3 different sets of animals for more 
than once and visually the clearest results were presented here. At all sets and 
runs, the results were the same. 
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Figure 4.2.4 2 Protein expressions of cell cycle genes in MSCs from control, 
163L and 163LR groups determined with Western blotting 
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CHAPTER 5 
 
 
DISCUSSION 
 
 
 
 
 
MSCs are ASCs that have self-renewal and differentiation capacity. These 
two properties are important both in regeneration of the damaged tissues and 
maintenance of the body stem cell pools. However, there are superior capacities of 
MSCs compared to the other types of ASCs. They have the homing capacity 
where they can migrate to the injured sites by sensing the chemokine gradient 
changes. Moreover when regeneration capacities of MSCs are considered, they 
can differentiate into the cells of mesenchymal lineage as well as other lineages 
like endodermal and ectodermal lineages such as pancreatic beta cells and nerve 
cells. MSCs can also mediate the differentiation of the other stem cells at the 
niche they migrate by their immunomodulatory effects. The immunomodulatory 
effects that MSCs exert on the cells of the damaged tissue have positive effects on 
the curing of the injury by inhibiting the T-cell, B-cell, DC and NK cell responses. 
Therefore use of MSCs is a valid option in the cure of autoimmune diseases and 
can be used as a supplementary treatment in transplantations. Furthermore, their 
regenerative capacities are well established in the treatment of ischemic heart 
diseases. Despite the fact that they are successful candidates in cardiovascular 
diseases their expansion in the culture in high amounts is an issue of concern and 
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limiting factor. Another important property of MSCs is their telomerase activity. 
Telomerase activity is known to have important effects on the survival and 
differentiation properties of MSCs and it is also important for their self-renewal. 
On the other hand telomerase activity is also present in cancer cells and there are 
effective cancer therapies targeting telomerase activity to demolish cancer cells 
without damaging the somatic cells. MSCs are one of the targets when these 
agents are administered since they possess telomerase activity. GRN163L is one 
of these agents, which prevents tumorigenesis in several cancer types, both in vivo 
and in vitro. The effects of GRN163L on stem cells have not yet been shown. In 
this study we aimed to show at first the best timing of the induction of 
cardiomyocyte differentiation in vitro by using MSCs and then the in vitro effects 
of GRN163L on MSCs. 
 
MSCs are promising agents for cellbased therapies however, there is no 
available data from experimental studies or clinical trials that shows the exact 
timing of the induction of cardiomyocyte differentiation prior to MSC delivery to 
an injured heart or ischemic limb. At the first part of this thesis we aimed to 
demonstrate the exact timing of the cardiomyocyte induction in vitro by using 
MSCs. For this purpose we first investigated the present conditions of the MSCs 
that are isolated from the bone marrow of the Sprauge-Dawley rats as a mixed 
culture. The undifferentiated state of the MSCs was proven by the presence of 
CD90 immunostaining and colony forming units at the 9
th
 and 14
th
 days of 
cultures. Further proof is provided by the measurement of the intracellular Ca
+2
 
levels. At 9
th
 and 14
th
 days of the culture before induction with 5-azacytidine, 
MSCs were treated with 10 mmol/L caffeine and 45-60 mmol/L KCl. Caffeine is 
known to exert its effects via ryanodine receptors that induce the increase in 
intracellular Ca
+2
 levels via IP3 pathway and KCl by depolarization. MSCs 
neither on the 9
th
 day nor on the 14
th
 day responded to any of the treatments 
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except ATP treatment which was applied as a positive control. As a result, we 
concluded that the cells do not show the properties of the differentiated cells in the 
culture prior to induction and they do not respond to depolarization and do not 
possess any ryanodin receptors. 
 
After proving the undifferentiated states of the cells, induction of 
cardiomyocyes was performed by 5-azacytidine treatment both on 9
th
 and 14
th
 
days of the culture and 14 days after the treatment the cells were checked for their 
differentiation status. At first the MSC marker CD90 expression was checked. If 
the cells were differentiated, they should no more express CD90 as a surface 
marker. The immunocytochemistry results demonstrated the expected result and 
the expression of CD90 was negative at 9
th
 and 14
th
 day groups. The contractility 
of the cells was then checked by determining the intracellular Ca
+2
 levels. The 
cells were treated with caffeine and KCl at the same amounts indicated before. 
Caffeine evoked no response neither on the cells induced at 9
th
 day nor at the 14
th
 
days of the culture. The ryanodine receptors were still not present on the 
differentiated cells as there was no increase in their intracellular Ca
+2
 levels 
measured by fura-2AM. Another reason for not observing evoke in intracellular 
Ca
+2
 levels via ryanodine receptors could be their continuous activation due to 
extensive phosphorylation, which could occur during the differentiation process. 
For a fully functional cardiomyocyte the proper functioning of ryanodine 
receptors should be achieved as ryanodine receptors are the main receptors for the 
release of  Ca
+2
 from the inrtacellular Ca
+2
 pools. However when the cells were 
treated with KCl, the response of the cells were observable to depolarization. The 
increase in Ca
+2
 levels was clearly observed with the cells induced to differentiate 
into cardiomyocytes  at day 9 and even more at day 14 indicating that the cells 
started to express voltage gated Ca
+2
 channels. 
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After checking the contractility of the cells specific for the cardiac muscle 
cells, expression of the cardiac troponin I, a-smooth muscle actin and MEF2D 
(myocyte specific enhancer factor 2D) that are markers specific to the cardiac 
cells were checked. MEF2D is a transcription factor that is important for the 
development of the cardiomyocytes and muscle cells. Cardiac troponin is specific 
to the cardiac cells and as well known, mediates the interaction between actin and 
myosin while a-sarcomeric actin is also important in contractility. According to 
the semi-quantitative RT-PCR results, the expression of the genes were higher 
than the control cells that were cultured in the control medium without 5-
azcytidine. Especially the increase at expression of the troponin I and sarcomeric 
actin were significant (p<0.05) on 9
th
 day, however on day 14 the expression was 
also present, but not significant. 
 
As a result, we were able to show that the MSCs were successfully able to 
differentiate into cardiomyocytes as early as day 9. This time is 5 days earlier than 
the normal culturing time of the MSCs. Shortening the culture period of MSCs 
could be useful especially for the patients waiting for urgent therapies that are 
suffering from ischemic heart diseases and may be very important as a cure for 
these diseases.  
 
The other life threatening disease is cancer as indicated by WHO and the 
targeted treatment of tumors is an issue of concern because the chemotherapeutics 
do not only kill the cancerous cells but also toxic to somatic cells. GRN163L is an 
oligonucleotide, a specific telomerase template antagonist, which binds to the 
telomerase RNA subunit and therefore inhibits the elongation of telomeres. 
Telomere maintenance is important for the survival of the cancer cells and when 
inhibited by GRN163L which also has a detachment effect on the cells, the drug 
effectively inhibits the proliferation of the telomerase expressing cancer cells, yet 
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MSCs also have telomerase activity and this activity is important for the 
maintenance of the stem cell pools and differentiation potentials.  
 
The effect of telomerase antagonist GRN163L on any adult stem cell is not 
demonstrated since its discovery in 2005. Treatment with a telomerase inhibitor 
could have some potential side effects on MSCs which are expected to be mild 
because stem cell populations have longer telomeres than tumor cells, and as they 
divide rarely, their telomeres should shorten at a much slower rate than 
proliferating cancer cells (Shay and Wright 2007). Therefore we aimed to reveal 
its effects on rat bone marrow derived MSCs when administered both in vivo and 
in vitro. For this purpose, we first investigated the phenotypic effects of 
GRN163L on MSCs. After the generation of the MSCs, the cells were seeded 
together in the presence of GRN163L and its mismatch oligonucleotide. When the 
treated cells were compared with the untreated MSCs that are control cells, it was 
observed that the treated cells were detached from the plate surface and get 
rounded instead of their attached spindle-like phenotype. Moreover although all 
the samples were seeded at the same number, control cells were growing 
continuously but the cells treated with the telomerase antagonist ceased growing. 
On the other hand the cells treated with mismatch oligonucleotide were behaving 
like the control cells in all manners. To check whether these effects on phenotype 
are reversible in vitro, we treated the cells for 3 days and then removed the drug 
and left the cells for recovery. Most of the cells recovered and gained their 
attachment and proliferative capacities and their fibroblastic shapes as well. These 
phenotypic effects of GRN163L are however supposed to be due to its properties 
of oligonucleotide backbone instead of the specific action on telomerase RNA 
subunit. On the other hand, its effects may be due to the inhibition of telomerase 
enzyme as telomerase independent from telomeres have other non-canonical roles 
in the cells. It was demonstrated that telomerase is important in the growth and 
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proliferation of the cells, by inducing the synthesis of growth factors (Smith et al 
2003), moreover it induces the mobility and differentiation of the stem cells and 
acts on the genes responsible in adhesion (Gilson and Ségal-Bendirdjian 2010). 
 
After determining the reversible effect on phenotype, we checked the MSC 
marker expressions of the treated, untreated, mismatch treated and recovered cells. 
CD90, CD29 and CD71 expressions were positive at all stages while CD34 and 
CD45 expressions were negative as determined by RT-PCR indicating that 
although the cells were treated with oligonucleotides either mismatch or 
GRN163L they do not differentiate or loose and decrease their marker 
compositions. Further investigation on telomerase activity is performed by using 
TRAP assay. The telomerase enzyme activity of the GRN163L treated cells was 
observed to have no telomeric ladders while the other cells, untreated, mismatch 
treated and recovered cells had telomeric ladders. Therefore we concluded that 
GRN163L like it does on cancer cells blocks the activity of telomerase in MSCs 
however when the cells are recovered the activity of the enzyme was regained and 
mismatch oligonucleotide had no effect on the enzymatic activity of telomerase. 
Our study independent from the effects of GRN163L on MSCs has also proven 
the telomerase activity of MSCs which is controversial in the literature as some 
studies indicate that MSCs do not possess telomerase but use ALT pathway 
instead and some of the reports indicate that MSCs show low level of telomerase 
expression and telomerase levels decrease with the increased passage. The latter is 
possible as unlike ESCs, MSCs can be passed upto 50 PDs and our study was 
performed with the cells at the first passage. 
 
The differentiation properties of MSCs were also checked after recovery. 
The reason to check the differentiation properties of the recovered cells depends 
on the fact that when the cells are treated in vivo they should maintain their 
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differentiation capacities to regenerate the damaged tissues. Also differentiation of 
the stem cells is an important signature of stemness. Furthermore the expression 
of telomerase in stem cells is important for their differentiation capacities. As 
GRN163L is active on telomerase it was important to determine the 
differentiation capacity to reveal whether any permanent effects were present on 
the telomerase activity. The adipogenic and osteogenic differentiation capacities 
of the control cells and recovered cells were checked and both cells were 
differentiated into osteocytes and adipocytes successfully as demonstrated with 
Alizarin Red S staining and Oil Red O staining respectively. So, we demonstrated 
that after the short term administration of GRN163L, when the cells were 
recovered from the effects of the drug, they still maintain their differentiation 
potentials in vitro. As telomerase is active on the differentiation potentials of the 
cells it was important to show the reversible nature of the telomerase inhibition. 
 
As indicated above the cells ceased growing when incubated with 1 µM 
GRN163L for 1 week. For this reason we also investigated the cell cycle genes to 
demonstrate at which step GRN163L was acting. The mRNA and protein 
expressions of the cells were checked by qRT-PCR and Western blotting 
respectively. In the combination of these results it was demonstrated that the cells 
were kept at G1 state of the cell cycle which is also reversible in vitro. Our results 
support the findings of Smith et al (2003), who showed the growth inducing 
effects of telomerase. 
 
MSCs are important candidates in cellular therapies they can be lifesaving 
in diseases that require urgent treatments however although our results revealed 
the reversible effects of GRN163L in vitro, extensive care must be taken to 
optimize the beneficial effects of the curative agents that can also affect MSC 
pools.
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CHAPTER 6 
 
 
FUTURE PERSPECTIVES 
 
 
 
 
In this thesis study the differentiation of cardiomyocytes as early as day 9 in the 
culture medium was achieved which was proven by the CD90 
immunocytochemistry, intracellular Ca
+2 
levels and the expression of 
cardiomyocyte specific markers. The functioning of voltage gated Ca
+2
 channels 
were seem to be achieved during the differentiation process, which was evidenced 
by elevation of intracellular Ca
+2
 levels after high extracellular KCl treatment. On 
the other hand, as caffeine treatment had no effect over the cells, we concluded 
that the ryanodine receptors, that have important role in the release of Ca
+2
 from 
intracellular Ca
+2
 pools, were not functioning. For this reason the formation and 
the functioning of the ryanodine receptors should be investigated with further 
studies from MSCs. 
 
The reversible activity of imetelstat on MSCs was revealed in this study as well. 
The reversible effects were proven by q-RT-PCR, immunobloting, differentiation 
protocols and TRAP assay. However all these procedures were conducted in vitro. 
GRN163L is an anticancer agent which is administered in combination with other 
antitherapeutics in clinical trials. Although all the effects of GRN163L on MSCs 
are reversible in vitro, the in vivo effects could be different. Therefore, the in vivo 
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effects of imetelstat should be determined in vivo with further studies to have a 
better understanding about the effect of GRN163L on MSC pools. 
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APPENDIX 
 
 
STANDARD SOLUTIONS AND BUFFERS 
 
DEPC-Treated ddH2O  
1ml DEPC 
1lt ddH2O 
Stirred in a hood for 1 hour, autoclaved in order to inactivate the DEPC 
 
10x PBS 
80 g NaCl 
2 g KCl 
8,01g Na2HPO4.2H2O 
2g KH2PO4 
1 liter ddH2O pH: 7,2 
Working solution (1XPBS) was prepared by diluting 10XPBS by 10 times 
 
50X TAE Buffer 
2M Tris Base (242 g) 
57,1 ml Glacial Acetic Acid 
50mM EDTA 
Add to 1 lt by ddH2O  
Working solution (1XTAE) prepared by diluting 50XTAE. 
 
10 X Agarose Gel Loading Dye 
0,009g BFB 
0,009g XC 
2,8mL ddH2O 
1,2ml 0,5M EDTA. 
Total volume brought to 15ml by adding glycerol, dilute 1:10 in sample 
prior to loading to electrophoresis gel 
 
10%SDS 
100g SDS  
1lt ddH2O 
 
1M Tris 
60.55g Tris  
300ml ddH2O 
 108 
21ml 37% HCl 
pH adjusted to 8.0 with HCl, total volume brought to 500ml by adding 
ddH2O. 
 
0.5M EDTA 
93.05g EDTA  
300ml ddH2O 
pH adjusted to 8.0 with NaOH, total volume brought to 500ml by adding 
ddH2O. 
 
30% Acrylamide Mix 
145g Acrylamide  
5g bis-acrylamide 
500ml ddH2O 
Filtered, stored in dark at 4
0
C. 
 
SDS-PAGE Running Buffer (5X stock solution) 
15g Tris 
73,2g Glycine 
5g SDS 
1lt ddH2O 
1X working solution prepared by diluting the 5X SDS-PAGE running 
buffer 5 times, stored at 4
0
C  
 
Bradford Reagent 
100 mg Coomassie Brilliant Blue G-250  
100 ml 85%phosphoric acid 
50 ml 95%EtOH 
850 ml ddH2O 
Filtered through Whatman no:1 
 
Lysis Buffer 
2M NaCl 
1M Tris pH:8.2 
0.9% Igepal CA-630 (Sigma, Germany) 
10x Protease Inhibitor Cocktail (Roche, Germany) 
778.5µl ddH2O 
 
10X TBS 
12.19 g Tris 
87,76 g NaCl 
pH adjusted to 8, total volume brought to 1lt by adding ddH2O 
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1X TBS-T 0.1% 
50 ml 10X TBS 
450 ml ddH2O 
1ml Tween-20 
Total volume brought to 500ml by adding ddH2O 
 
Blocking Solution for Western Blot (5%) 
2,5 g milk powder 
50mL 1X TBS-T(0.1%) 
 
5% BSA Blocking Solution 
0.5g BSA 
10mL 1X TBS-T(0.1%) 
 
Blocking Solution for Immunohistochemistry and 
Immunoflourescence Staining 
4 µl 2% BSA 
4 µl 1X PBS 
20 µl Tween-20 
 
1XPBS-T (0.1%) 
500ml 1XPBS 
0.5ml Tween-20 
 
Cracking Buffer (2X Protein Loading Buffer) 
50mM Tris HCl pH: 6,8 
2mM EDTA pH: 6,8 
1% SDS 
20% Glycerol 
0,02% BFB 
Add 1% ß-mercaptoethanol prior to use 
 
Coomassie Blue Staining Solution: 
0,25 g coomassie brilliant blue 
45 ml Methanol 
45 ml ddH2O 
10 ml glacial acetic acid 
 
5X Running Buffer 
15 g Tris base 
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72 g Glycine 
5 g SDS 
1 liter ddH2O 
Diluted to 1X prior to use 
 
Semi-dry Transfer Buffer 
2,5 g glycine 
5,8 g Tris base 
0,37 g SDS 
200 ml methanol 
800 ml ddH2O 
 
Destaining Solution 
100 ml methanol 
35 ml acetic acid 
365 ml ddH2O 
 
Cold 70% Ethanol 
70 ml Ethanol  
30 ml ddH2O 
Dissolved and keep at 4°C 
 
4% PFA 
4g PFA  
100ml 1XPBS  
Dissolved by heating, solution prepared freshly 
Timing of induction of cardiomyocyte
differentiation for in vitro cultured mesenchymal
stem cells: a perspective for emergencies1
Zeynep Tokcaer-Keskin, A. Ruchan Akar, Fatma Ayaloglu-Butun, Ece Terzioglu-
Kara, Serkan Durdu, Umit Ozyurda, Mehmet Ugur, and Kamil C. Akcali
Abstract: Mesenchymal stem cells (MSCs) have the capacity to differentiate into osteoblasts, chondrocytes, adipocytes,
myocytes, and cardiomyocytes. Several established methods are presently available for in vitro isolation of MSCs from
bone marrow. However, the duration necessary to culture them can be a major handicap to cell-based therapies needed for
such urgent cardiovascular conditions as acute myocardial infarction and acute hindlimb ischemia. The best timing of car-
diomyocyte differentiation induction after MCS isolation and expansion is still an unresolved issue. Our goal was to inves-
tigate the possibility of obtaining functional cardiomyocytes from rat MSC within a shorter time period. We examined
MSCs’ colony-forming capacity, CD90 and CD34 immunoreactivity during the 14 days of culturing. Cardiomyocyte differ-
entiation was induced by 5-azacytidine. Immunohistochemic staining, together with intracellular Ca2+ measurement experi-
ments, revealed that MSCs do not differentiate into any specific cell lineage but show the characteristics of MSCs on both
the 9th and 14th days of the culture. To check the potential for differentiation into cardiomyocytes, experiments with caf-
feine application and depolarization with KCl were performed. The cells possessed some of the specific biochemical fea-
tures of contracting cells, with slightly higher capacities on the 14th day. Cells from 9th and 14th days of the culture that
were treated with 5-azacytidine had a higher expression of cardiac-specific markers such as troponin I, a-sarcomeric actin,
and MEF2D compared with the control groups. This study illustrates that it is possible to get functional cardiomyocytes
from in vitro MSC culture in a shorter time period than previously achieved. This reduction in time may provide emer-
gency cases with access to cell-based therapies that may have previously been unavailable.
Key words: mesenchymal stem cells, cardiomyocytes, differentiation, rat, in vitro, gene expression.
Re´sume´ : Les cellules souches me´senchymateuses (CSM) ont la capacite´ de se diffe´rencier en oste´oblastes, chondrocytes,
adipocytes, myocytes et cardiomyocytes. Plusieurs me´thodes e´prouve´es permettent d’isoler in vitro les CSM de la moelle
osseuse. Toutefois, la dure´e requise pour leur culture pourrait eˆtre un de´savantage majeur pour la the´rapie cellulaire d’ur-
gences cardiovasculaires comme l’infarctus du myocarde et l’ische´mie des membres infe´rieurs. Le meilleur moment de
l’induction de la diffe´renciation des cardiomyocytes apre`s l’isolement et l’expansion des CSM n’a toujours pas e´te´ de´ter-
mine´. Nous avons e´tudie´ la possibilite´ d’obtenir des cardiomyocytes fonctionnels de CSM de rats sur une courte pe´riode
de temps. Nous avons examine´ la capacite´ de formation de colonies des CSM et l’immunore´activite´ a` CD90 et CD34 du-
rant les 14 jours de culture. La diffe´renciation en cardiomyocytes a e´te´ induite par la 5-azacytidine. La coloration immuno-
histochimique ainsi que des mesures du Ca2+ intracellulaire ont re´ve´le´ que les CSM ne se diffe´rencient pas en une ligne´e
cellulaire spe´cifique, mais montrent les caracte´ristiques des CSM lors des 9e et 14e jours de culture. Pour ve´rifier le poten-
tiel de diffe´renciation en cardiomyocytes, nous avons fait des expe´riences avec application de cafe´ine et de´polarisation au
KCl. Les cellules posse´daient certaines des caracte´ristiques biochimiques spe´cifiques des cellules pouvant se contracter,
avec des capacite´s le´ge`rement supe´rieures le quatorzie`me jour. Les cellules des 9e et 14e jours de culture traite´es avec la
5-azacytidine ont montre´ une plus grande expression de marqueurs spe´cifiques du cœur, tels que la troponine I, l’actine
a-sarcome´rique et MEF2D, comparativement a` celles des groupes te´moins. Cette e´tude montre qu’il est maintenant pos-
sible d’obtenir des cardiomyocytes fonctionnels d’une culture in vitro de CSM dans une courte pe´riode de temps. Cette re´-
duction de temps pourrait fournir aux cas d’urgence un acce`s a` des the´rapies cellulaires jusqu’alors inaccessibles.
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[Traduit par la Re´daction]
_______________________________________________________________________________________
Introduction
Stem cell research has gained tremendous interest in the
past two decades because it provides opportunities to de-
velop new strategies for debilitating diseases. Stem, or pro-
genitor, cells have the potential to provide unique sources
for tissue restoration in regenerative medicine and tissue en-
gineering (Ivanova et al. 2002). Although self-renewal and
differentiation are their common features, as a result of cell-
to-cell communication, stem cells vary in their potential to
differentiate, in their duration and pathways of self-renewal,
in the places where they are mostly found, and in their divi-
sional characteristics (Morrison et al. 1997).
Autologous stromal mesenchymal stem cells (MSCs) from
bone marrow, first identified by Friedenstein in the 1970s
(Friedenstein et al. 1974, 1976), may offer the possibility of
a renewable source for the replacement of injured cells or
tissues without raising ethical concerns or the possibility of
immunologic reactions. MSCs are a very small fraction of
the nucleated cells in the bone marrow, only 0.01%–0.1%
of the total population (Pittenger et al. 1999). They have fi-
broblastic morphology and they are adherent spindle-shaped
cells. MSCs adhere to the culture plate, leading to the for-
mation of colonies. Usually, basal mediums with serum sup-
port are used to expand MSCs in tissue culture, and growth
factors are added in order for MSCs to differentiate (Barry
and Murphy 2004). In fact, their most prominent feature is
their ability to differentiate into osteoblasts, chondrocytes,
adipocytes, hepatocytes, neurons, and myocytes under de-
fined conditions. They are also thought to differentiate into
certain types of ectodermal and endodermal tissues, such as
neurons and endothelial cells, including skeletal myocytes
(Jackson et al. 2001), central and peripheral neurons (Mezey
et al. 2000; Brazelton et al. 2000), and hepatic cells (Petersen
et al. 1999). The master switches regulating the transitions
from stem cells to differentiated cells, and the genes active
in specific differentiation patterns are still not known. The
reason for the difficulty in finding these regulatory genes is
because of their temporal activity, the response given to in-
ductive molecules, and the varying differentiation pathways
between organisms (Baksh et al. 2004; Caplan and Bruder
2001).
Bone marrow-derived cardiac myocytes have been shown
to populate rodent heart tissue after myocardial infarction
(Jackson et al. 2001) or cardiac transplantation (Edelberg et
al. 2002). Moreover, preclinical studies have shown that the
injection of bone marrow cells directly into the myocardium
enables these cells to differentiate into cardiac myocytes,
smooth muscle cells, and endothelial cells. These transforma-
tions lead to the regeneration of the myocardium and improve-
ment of cardiac function (Orlic et al. 2001; Tomita et al. 2002).
A major roadblock in the use of MSCs, however, is that
MSCs are rare and the long duration of their culture limits
their potential use in urgent cell-based therapies. In addition,
the assessment of donor MSC functional activity at the cel-
lular level, which is the focus of several research groups, is
critically important. To our knowledge, no study has looked
at the best timing to induce cardiomyocyte differentiation
after MSC isolation and expansion. Therefore, we aimed to
shorten the time period required for MSC culture before car-
diomyocyte differentiation.
Materials and methods
Cell culture
MSCs were obtained from female, 9-week-old, 280–300 g
Sprague–Dawley rats. Bone marrow heterogeneous cell pop-
ulation was collected from the femur and tibia by flushing
with a 5-millilitre syringe containing 10% FBS (HyClone,
Logan, USA) in DMEM (Invitrogen, Paisley, UK) after the
rats were sacrificed by cervical dislocation. Negatively se-
lected supernatant from CD34-labeled paramagnetic beads
(Dynal, Oslo, Norway) was cultured in plastic cell-culture
dishes with MesenCult medium (StemCell Technologies,
Vancouver, Canada) with a 20% supplement (StemCell
Technologies) and a 1% penicillin–streptomycin solution
(HyClone) in a 5% CO2 incubator at 37 8C. The next day,
the media of the tissue culture plates were changed and the
nonadherent cells were removed. The media of the cells
were changed every 4 days, after washing with sterile 1
PBS before the change.
Our experimental study protocol was approved by the An-
imal Ethics Committee of Bilkent University (Bil-AEC). All
the animals received care according to the criteria outlined
in the Guide for the Care and Use of Laboratory Animals
prepared by the National Academy of Science, and this
study protocol complied with Bilkent University’s guidelines
on the humane care and use of laboratory animals.
Colony-forming assay
MSCs were washed in 1 PBS and then air dried. Meth-
anol was used for fixation and left for 5 min. The cells were
washed again in a 1 PBS buffer and a giemsa-staining re-
agent (Carlo Erba, Milano, Italy) was added and left for
5 min. The reaction of the giemsa staining was stopped by
the addition of tap water.
Induction of cell differentiation
Two different time points were used for the cardiomyo-
cyte differentiation of MSCs. In the first group, differentia-
tion was induced on day 9 of the culture (hereafter stated as
the 9th day) and in the second group, differentiation was in-
duced on day 14 (hereafter stated as the 14th day). The in-
duction of cardiomyocyte differentiation was performed by
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incubating cells with 10 mmol/L 5-azacytidine (Sigma,
Steinheim, Germany) for 24 h. The cells were washed
and expanded for another 14 days with low-glucose
DMEM (Invitrogen), 20% FBS (HyClone), and 1%
penicillin-streptomycin (HyClone).
Total RNA isolation and RT-PCR analysis
On the 9th and 14th day of the MSC culture and 14 days
after the 5-azacytidine treatment of each group, cells were
trypsinized and removed. Total cellular RNA was isolated
from the precipitate by using the RNeasy Mini kit (Qiagen,
Table 1. Primers and the product size of the cardiac-specific gene markers for cDNA amplifi-
cation.
Gene Primers Product size
Troponin I Forward: 5’–GCGAAGCAGGAGATGGAG–3’ 250 bp
Reverse: 5’–TGCCACGCAGGTCATAGA–3’
a-Sarcomeric actin Forward: 5’–CCAGGCACTGTGGAAAGG–3’ 115 bp
Reverse: 5’–CACGATGGATGGGAAGAC–3’
MEF2D Forward: 5’–TGGGAATGGCTATGTCAGTG–3’ 351 bp
Reverse: 5’–CTGGTAATCTGTGTTGTAGG–3’
GAPDH Forward: 5’–CCTCCTCATTGACCTCAACTAC–3’ 219 bp
Reverse: 5’–CATGGTGGTGAAGACGCCAG–3’
Table 2. PCR conditions for the genes.
Gene Initial denaturation Denaturation Annealing Extension Cycles Final extension
Troponin I 95 8C, 5 min 94 8C, 45 s 65 8C, 30 s 72 8C, 40 s 33 72 8C, 5 min
a-Sarcomeric actin 95 8C, 10 min 94 8C, 45 s 57 8C, 60 s 72 8C, 60 s 35 72 8C, 10 min
MEF2D 95 8C, 10 min 94 8C, 30 s 57 8C, 60 s 72 8C, 50 s 33 72 8C, 5 min
GAPDH 95 8C, 5 min 94 8C, 30 s 59 8C, 30 s 72 8C, 30 s 23 72 8C, 5 min
Fig. 1. Characteristics of rat mesenchymal stem cells on the 9th day of culture. (A) CD90 immunoreactivity and colony-forming capacity.
No staining is observed in the negative control. (B) Cytoplasmic calcium levels in response to KCl and caffeine measured with fura-2. No
response was observed with either stimulation. ATP stimulation is used as a positive control. Fura-2 signal is given as a ratio of fluores-
cence at 340 and 380 nm.
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Hilden, Germany) according to the manufacturer’s protocol.
The cDNAs were synthesized from the total RNA samples
with the RevertAid First Strand cDNA synthesis kit (MBI
Fermentas, Canada) according to the manufacturer’s proto-
col. cDNA amplifications were performed by using oligonu-
cleotide primers for the following genes: cardiac troponin I
(cTnI), a-sarcomeric actin, MEF2D, and GAPDH (Table 1).
PCR conditions of these genes are listed in Table 2.
Immunohistochemistry
Cells in the cover slips were incubated for 30 min in 0.3%
hydrogen peroxide in methanol to quench endogenous perox-
idase activity. After washing 3 times with PBS for 10 min
each, slides were incubated with preblocking serum (normal
goat serum 1.5%, bovine serum albumin 2%, Triton X-100
0.1%) for 1 h at room temperature. Primary antibodies of
CD90 and CD34 (Chemicon, Temecula, Canada) were ap-
plied at a concentration of 1:500 dilution in preblocking sol-
ution and kept at 4 8C overnight. After washing 3 times with
PBS, tissue sections were incubated for 15 min each with bi-
otinylated anti-mouse and anti-rabbit Ig (DakoCytomation,
Glostrup, Denmark) and streptavidin – horseradish peroxi-
dase (HRP) (DakoCytomation) at room temperature. After
washing for 10 min with PBS, slides were rinsed in a 0.5%
solution of Triton X-100 and PBS for 30 s. Color develop-
ments were achieved by incubation with liquid DAB+ (Da-
koCytomation). The slides were then counterstained with
hematoxylin and mounted with Faramount aqueous mount-
ing medium (DakoCytomation).
Intracellular Ca2+ measurement
Cells were grown on round cover slips in 6-well plates
and loaded with fura-2 AM at room temperature (21–24 8C)
for 50 min. Cells were then washed before the experiments
with Hepes-buffered physiologic NaCl bathing solution con-
taining 1.2 mmol/L Ca2+ and 1 mmol/L Mg2+. Cells were
challenged either with caffeine to stimulate ryanodine recep-
tors or with ATP to stimulate P2Y purinergic receptors. In
addition, we applied high-KCl bathing solutions and moni-
tored intracellular calcium concentrations to see whether de-
polarization could induce any intracellular Ca2+ transients.
Cover slips were fixed to a Teflon chamber and mounted
on an inverted fluorescent microscope (Nikon TE-300,
Japan). Fluorescence ratios were obtained by exciting cells
at 340 and 380 nm with a microscope-based spectro-
fluorimeter with a temporal resolution of one ratio every
0.5 s. Emission signals were collected at 510 nm with an
IC-300 ICCD (intensified charge-coupled device) camera
with Delta Ram, (Photon Technology International, USA).
Data was collected and analyzed by Image Master software
(Photon Technology International).
Statistical analysis
All data were expressed as means ± SD. Data were ana-
Fig. 2. Characteristics of rat mesenchymal stem cells on the 14th day of culture. (A) CD90 immunoreactivity and colony-forming capacity.
No staining is observed in the negative control. (B) Cytoplasmic calcium levels in response to caffeine (or KCl, data not shown) measured
with fura-2. No response was observed with either stimulation. ATP stimulation is used as a positive control. Fura-2 signal is given as a
ratio of fluorescence at 340 and 380 nm.
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lyzed by performing paired t test using Minitab Statistical
Software (State College, USA). A value of p < 0.05 was
considered to be statistically significant.
Results
We first investigated the characteristics of MSCs on the
9th and 14th days of the culture by their CD90 expressions
and CFU-F (colony-forming unit – fibroblast) activities
(Figs. 1A and 2A). We also compared their free intracellular
Ca2+ concentrations (Figs. 1B and 2B). On the 9th day of
the culture, rat MSCs were stained positive for CD90
(Fig. 1A), started to form colonies (Fig. 1A), and did not
evoke any Ca2+ response upon application of caffeine and
depolarization with KCl (Fig. 1B). These results were simi-
lar to those on the 14th day of the culture, confirming that
both cells were undifferentiated (Figs. 2A and 2B). On the
other hand, they responded to (0.5  10–4 mol/L) extracellu-
lar ATP application with a clear Ca 2+ transient (Figs. 1B
and 2B). These cells stained negative with the CD34 anti-
body (data not shown).
Next, MSCs from the 9th and 14th days of the culture
were treated with 5-azacytidine to induce cardiomyocyte dif-
ferentiation. Fourteen days after this treatment, we checked
their CD 90 expressions (Figs. 3A and 4A) and their re-
sponses to extracellular KCl and caffeine as an increase in
cytosolic Ca2+ was noted after the cells were loaded with
fura-2 (Figs. 3B and 4B). We applied 10 mmol/L caffeine
and 45–60 mmol/L extracellular KCl to the cells. Cells
treated with 5-azacytidine on the 9th and 14th days of the
culture did not respond to 10 mmol/L caffeine. On the other
hand, cells treated with 5-azacytidine on the 14th day of the
culture responded to the KCl application with a small in-
crease of cytosolic Ca2+. Cells treated with 5-azacytidine on
the 9th day also responded with a very small Ca2+ increase.
These results may suggest that voltage-activated Ca2+ chan-
nel expression is starting in both groups of cells 14 days
after the 5-azacytidine treatment; however, there is no indi-
cation of the presence of functional ryanodin receptors. All
cells responded to ATP (0.5  10–4 mol/L) application with
a sudden cytoplasmic Ca2+ increase.
To illustrate the cardiomyocyte commitment of these
cells, we performed RT-PCR analysis to investigate the ex-
pression pattern of cardiac-specific markers before and after
the induction with 5-azacytidine. RT-PCR experiments
showed that cardiac-specific troponin1, a-sarcomeric actin,
and MEF2D expression increased after the 5-azacytidine in-
duction compared with that of the cells that were cultured
with the control media both on the 9th day (Fig. 5A) and
the 14th day of the culture (Fig. 5B). The expression of car-
diac-specific troponin1 and a-sarcomeric actin were statisti-
cally significant on the 9th day compared with that of the
Fig. 3. Differentiation into cardiomyocytes was induced by applying 5-azacytidine to MSCs on the 9th day of culture. (A) No CD90 im-
munoreactivity is present after induction. (B) Cytoplasmic calcium levels in response to KCl and caffeine measured with fura-2. ATP sti-
mulation is used as a positive control. Fura-2 signal is given as a ratio of fluorescence at 340 and 380 nm.
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control group. The values shown in Figs. 5A and 5B were
obtained by normalizing the expression values to that of the
loading control, GAPDH.
Discussion
The possibility of using stem cell-based therapies has
opened a new therapeutic era for cardiovascular diseases,
which claim roughly as many lives as cancer, chronic lower
respiratory diseases, accidents, diabetes mellitus, influenza,
and pneumonia combined (1999–2002 National Health and
Nutrition Examination Survey, available from www.ameri-
canheart.org, ‘‘Heart disease and stroke statistics, 2005 up-
date’’). Applications involving the use of stem cells in
humans, which might have been considered ‘science fiction’
fewer than 20 years ago, are now being utilized with a great
success rate (Akar et al. 2006). Different types of stem or
progenitor cells have been used to target cardiac regenera-
tion, including MSCs (Laflamme and Murry 2005; Tousou-
lis et al. 2008; Wang and Li 2007; Atsma et al. 2007;
Ohnishi and Nagaya 2007). Aside from their differentiation
potential, there are other aspects that make MSCs valuable
for new therapeutic strategies. MSCs actively inhibit T-cell
proliferation and as a result are considered nonimmunogenic
or hypoimmunogenic, which is important for a host response
to allogenic MSC therapy. MSCs can also be frozen to pre-
serve them, and when they are thawed they function appa-
rently normally, thus allowing for future ‘off-the-shelf’
therapy approaches. However, the time required for isola-
tion, expansion, and differentiation of specific cell types
can be a major handicap to the optimal timing of stem-cell
delivery to acutely injured tissues or organs. This issue is of
paramount importance in cardiovascular medicine (Bartunek
et al. 2006). The assessment of donor MSC functional activ-
ity at the cellular level, which is the focus of several re-
search groups, is also critically important. There are no
available data from experimental studies or clinical trials
that show the exact timing of the induction of cardiomyo-
cyte differentiation before MSC delivery to an injured heart
or ischemic limb.
Our study demonstrated that rat MSCs did not differenti-
ate but exhibited characteristics of MSCs by the 9th day of
the culture similar to those on the 14th day of the culture.
As expected, these cells started to form colonies on day 7
(data not shown) and these colonies became positive for
CD90 staining by day 9. We observed that caffeine
(10 mmol/L) application and depolarization with KCl (45–
60 mmol/L) did not evoke any Ca2+ responses in MSCs on
the 9th and 14th days of the culture, which confirmed that
they were still undifferentiated cells. On the other hand,
they responded to extracellular ATP (0.5  10–4 mol/L) ap-
plication with clear Ca2+ transients. These results indicate
the absence of any functional ryanodine receptor in rat
MSCs and also demonstrate that these cells do not differen-
tiate and clearly exhibit characteristics of MSCs by the 9th
day of the culture. Therefore, 9 days of in vitro isolation
and expansion of MSCs can be adequate for the application
of any differentiating agents to these cells. To our knowl-
edge, this is the shortest time yet that obtains functional
MSCs in rat models. Shortening the culture time by nearly
Fig. 4. Differentiation into cardiomyocytes was induced by applying 5-azacytidine to MSCs on the14th day of culture. (A) No CD90 im-
munoreactivity is present after induction. (B) Cytoplasmic calcium levels in response to KCl and caffeine measured with fura-2. ATP sti-
mulation is used as a positive control. Fura-2 signal is given as a ratio of fluorescence at 340 and 380 nm.
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5 days could be a very useful development for patients
awaiting urgent cell-based therapies.
In this study we also demonstrated that MSCs could be
differentiated into cardiomyocyte-like cells by applying
5-azacytidine in vitro (Makino et al. 1999) and in vivo
(Toma et al. 2002; Shake et al. 2002), as shown previ-
ously. However, the exact mechanism of MSCs’ differen-
tiation into cardiomyocyte-like cells is not clear. Several
groups have reported that in vitro differentiation of MSCs
into cardiomyocytes depends on different factors, including
the number of passages or the combination of certain
growth factors or molecules (Zhang et al. 2005; Antonitsis
et al. 2007; Muscari et al. 2008).
To further characterize the cardiomyocyte differentiation,
MSC cultures from day 9 and day 14 were treated with
10 mmol/L 5-azacytidine to induce cardiomyocyte differen-
tiation (Figs. 3 and 4). Fourteen days after the 5-azacytidine
treatment, we observed that these cells, both on the 9th
(Fig. 3A) and 14th (Fig. 4A) days of the culture, did not ex-
press the mesenchymal stem cell marker CD90. Both groups
responded, albeit slightly, to extracellular KCl with an in-
crease in cytosolic Ca2+; however, this response appeared to
be more evident on the 14th day of the culture. On the other
hand, cells from both cultures did not respond to 10 mmol/L
caffeine application, but responded to ATP (0.5 10–4 mol/L)
application with a sudden cytoplasmic Ca2+ increase
(Figs. 3B and 4B), probably due to the stimulation of en-
dogenous P2Y receptors. These results may suggest that
voltage-activated Ca2+ channel expression starts 14 days
after the 5-azacytidine treatment on the 9th and 14th days
of the culture, but there is no indication of the presence of
functional ryanodin receptors. Further experiments are
needed to verify this point. It is noteworthy that compared
with the controls, both the 9th- and 14th-day 5-azacytidine-
treated cells expressed increased levels of cardiomyocyte-
specific genes (Figs. 5A and 5B). The increase in the
expression of cardiac-specific troponin1 (p = 0.039) and
a-sarcomeric actin (p = 0.012) on the 9th day was statisti-
cally significant. These findings suggest that MSCs from
day 9 may be used for the in vitro differentiation into car-
diomyocytes.
In conclusion, our study demonstrated that MSCs from
adult rat bone marrow are able to differentiate into cardio-
myocyte-like cells as early as 9 days after isolation and ex-
pansion after being induced by 5-azacytidine, evidenced by
expressing cardiomyocyte-specific genes and losing the ex-
pression of mesenchymal stem cell marker genes. These re-
sults indicate that the culture time for MSCs can be
shortened by nearly 5 days, which could be useful for pa-
tients awaiting urgent cell-based therapies.
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Abstract Telomerase activity is essential for the continued
growth and survival of malignant cells, therefore inhibition
of this activity presents an attractive target for anti-cancer
therapy. The telomerase inhibitor GRN163L, was shown to
inhibit the growth of cancer cells both in vitro and in vivo.
Mesenchymal stem cells (MSCs) also show telomerase
activity in maintaining their self-renewal; therefore the
effects of telomerase inhibitors on MSCs may be an issue
of concern. MSCs are multipotent cells and are important
for the homeostasis of the organism. In this study, we
sought to demonstrate in vitro effects of GRN163L on rat
MSCs. When MSCs were treated with 1 µM GRN163L,
their phenotype changed from spindle-shaped cells to
rounded ones and detached from the plate surface, similar
to cancer cells. Quantitative-RT-PCR and immunoblotting
results revealed that GRN163L holds MSCs at the G1 state
of the cell cycle, with a drastic decrease in mRNA and
protein levels of cyclin D1 and its cdk counterparts, cdk4
and cdk6. This effect was not observed when MSCs were
treated with a mismatch control oligonucleotide. One week
after GRN163L was removed, mRNA and protein expres-
sions of the genes, as well as the phenotype of MSCs
returned to those of untreated cells. Therefore, we conclud-
ed that GRN163L does not interfere with the self-renewal
and differentiation of MSCs under short term in vitro
culture conditions. Our study provides additional support
for treating cancers by administrating GRN163L without
depleting the body’s stem cell pools.
Keywords Mesenchymal stem cells . Telomerase .
Cyclin D1 . cdk4 . cdk6 . GRN163L
Introduction
Telomerase is a ribonucleoprotein complex consisting of a
reverse transcriptase catalytic subunit (hTERT) and an
RNA moiety (hTR or hTERC). The template region of
hTR is complementary to telomeric DNA and together with
hTERT elongates telomeres by adding TTAGGG repeats to
the end of the chromosome. This leads to stabilization of
telomere lengths, prevention of t-loop and overhang loss,
and continued cell division [1, 2]. Telomerase activity is
reduced or absent in majority of normal tissues, which leads
to a progressive shortening of the telomere with each cell
division. In contrast, tumor cells and self-renewable tissues
express telomerase to sustain their growth. The presence of
this activity in many different kinds of human tumors, but
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not in normal somatic cells, makes inhibition of telomerase
activity an attractive tool on targeted cancer therapy [3–5].
Experimental studies based on anti-telomerase cancer
therapies, such as immunotherapy, gene therapy, small
molecule inhibitors and oligonucleotide-based therapeutics
[3–5] have been making progress in recent years. A novel
human telomerase RNA (hTR) antagonist GRN163L (Ime-
telstat) is a lipid-modified N3′→P5′ thio-phosphoramidate
that is complementary to the template region of hTR,
preventing it from binding to the telomeric repeats. The
GRN163L sequence (5′-Palm-TAGGGTTAGACAA-3′) is
apparently unique in the human transcriptome, and shows
greatly enhanced stability as well as specific and high-
affinity binding to telomerase. It has been shown that
GRN163L causes telomerase inhibition and subsequent
telomere shortening in many cell types, including in breast
cancer, lung cancer, multiple myeloma and non-Hodgkin’s
lymphoma cell lines [6–8]. GRN163L has recently entered
into Phase I/II clinical trials in patients with chronic
lymphocytic leukaemia and some solid tumors such as in
lung and breast cancer. Despite being a promising thera-
peutic agent, inhibition of telomerase activity may lead to
side effects since germline cells, proliferating stem and
progenitor cells also exhibit telomerase activity. Thus
inhibition of telomerase could potentially cause a decline
or defect in regenerative capacity and organ homeostasis
[9].
Mesenchymal stem cells (MSCs) are multipotent cells
capable of self-renewal and differentiating into multiple
lineages such as osteocytes, adipocytes, chondrocytes,
myoblasts, cardiomyocytes [10–12]. MSCs are also prom-
ising agents for cell-based therapies due to their ability to
migrate in vivo to promote regeneration of damaged tissue,
treat inflammation, and promote angiogenesis without
inducing immune reaction in addition to the lack of ethical
concerns [13, 14]. Additionally, their high self-renewal
potential makes them strong candidates for stem cell gene
therapy treating acquired and inherited disorders and
restoring organ system functions, since tissue repair and
regeneration is made possible by the presence of adult stem
cells [15]. For the above reasons, the effects of telomerase-
targeting therapies on MSCs must be well defined. The
present study was undertaken to investigate the in vitro
effects of GRN163L on the self-renewal and differentiation
processes of MSCs.
Materials and Methods
Isolation and Culture of MSCs
MSCs were obtained from female, 9-week-old, 280–300 g
Sprague–Dawley rats. After the rats were sacrificed by
cervical dislocation, bone marrow a heterogeneous cell
population was collected from the femurs and tibias by
flushing with a 5 mL syringe containing 10% FBS
(HyClone, Logan, USA) in DMEM (HyClone). The cells
were cultured in plastic cell-culture dishes with MesenCult
medium (StemCell Technologies, Vancouver, Canada) with
a 20% supplement (StemCell Technologies) and a 1%
penicillin–streptomycin solution (HyClone) in a 5% CO2
incubator at 37°C. The next day, the media of the tissue
culture plates were changed and the nonadherent cells were
removed. The media of the cells were changed every
3 days, after washing with sterile 1x PBS. Our experimental
study protocol was approved by the Animal Ethics
Committee of Bilkent University (BILHADYEK). All the
animals received care according to the criteria outlined in
the Guide for the Care and Use of Laboratory Animals
prepared by the National Academy of Science of the USA,
and this study protocol complied with Bilkent University’s
guidelines on the humane care and use of laboratory
animals.
Experimental Groups
After 14 days of culture, the cells were trypsinized
(HyClone) and transferred to culture dishes for RNA and
protein isolation as well as for differentiation and telomer-
ase activity assays. One day after the transfer, GRN163L
(Geron Co., CA, USA) and its mismatch control oligo were
added at a concentration of 1 µM to the cell plate. The
media were changed every 3 days with the fresh GRN163L
(hereafter stated as 163 L group) and mismatch control
oligonucleotide (hereafter stated as mismatch group) to-
gether with control MSCs with no treatment (hereafter
stated as control group). 163 L and mismatch cultures
continued for 1 week. Finally, MSCs were left for recovery
for 1 week after GRN163L was removed (hereafter stated
as 163LR (recovery) group).
Total RNA Isolation and Reverse Transcription
MSCs were trypsinized and the total cellular RNA was
isolated from the precipitate by using the RNeasy Mini kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
protocol, with additional DNase treatment. The cDNAs
were synthesized from the total RNA samples with the
DyNAmo cDNA synthesis kit (Finnzymes, Espoo, Finland)
according to the manufacturer’s protocol.
RT-PCR
cDNA amplification for CD90, CD71, CD45, CD34, CD29
and cyclophilin were performed by using DyNAzyme II
(Finnzymes). The primers are listed in Table 1. The initial
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denaturation step was at 95°C for 5 min, followed by 30
(for CD90 and CD34), 35 (for CD 71), 26 (for CD29 and
CD45) and 23 (for cyclophilin) cycles of denaturation for
30 s for all genes at 94°C, annealing for 30 s at 55°C (for
CD90, CD34 and cyclophilin), 60 s at 66°C (for CD71) and
30 s at 60°C (for CD29 and CD45), followed by extension
for 30 s (for CD90, CD34, CD29, CD45 and cyclophilin)
and 45 s (for CD71) at 72°C. A final extension at 72°C for
5 min was applied to all the reactions.
Q-RT-PCR
The primers used for Q- RT-PCR are shown in Table 1.
Before performing Q- RT-PCR reactions for experimental
samples, the amplification efficiencies of all primers were
calculated using a standard dilution series. Fold changes
in the expression of the genes were estimated based on
the comparative Ct 2ΔΔCt
 
method, using the normal
MSCs as calibrator. The Q- RT-PCR conditions for all
Gene Sequence Product size (bp)
TERT (F) 5′-GCTACGCCATCCTGAAGGTC-3′ 99
(R) 5′-GGTAGCAGAGCCAACGTGTG-3′
CYCLIN B1 (F) 5′-TCGATGTGGAGCAGCATACT-3′ 142
(R) 5′-GTCCATTCACCGTTGTCAAG-3′
CDK4 (F) 5′-GAAGACGACTGGCCTCGAGA-3′ 109
(R) 5′-ACTGCGCTCCAGATTCCTCC-3′
CDK6 (F) 5′-TTGTGACAGACATCGACGAG-3′ 151
(R) 5′-GACAGGTGAGAATGCAGGTT-3′
CDK2 (F) 5′-TGACCAACTCTTCCGGATCT-3′ 164
(R) 5′-ATAACAAGCTCCGTCCGTCT-3′
CDK1 (F) 5′-GTTGACATCTGGAGCATAGG-3′ 144
(R) 5′-CTCTACTTCTGGCCACACTT-3′
CYCLIN A2 (F) 5′-CTGCCTTCCACTTAGCTCTC-3′ 125
(R) 5′-GAGGTAGGTCTGGTGAAGGT-3′
RB (F) 5′-TTGAAAGAAGAGGCACTCCC-3′ 116
(R) 5′-CGCTACCTTAAATACCGCCT-3′
P53 (F) 5′-GTTCCGAGAGCTGAATGAGG-3′ 109
(R) 5′-AGACTGGCCCTTCTTGGTCT-3′
Bmi-1 (F) 5′-ATGTGTGTCCTGTGTGGAGG-3′ 281
(R) 5′-AGCCATTGGCAGCATCTGCT-3′
P21 (F) 5′-ATGTCCGATCCTGGTGATGTC-3′ 92
(R) 5′-CGGCTCAACTGCTCACTGTC-3′
Cdc25a (F) 5′-AGTGAAGAGAGCAGACCGAT-3′ 126
(R) 5′-GGAGAGAGACTGGTGTGGAA-3′
P16INK4a (F) 5′-CTTCACCAAACGCCCCGAACA-3′ 132
(R) 5′-CGGGAGAGGGTGGTGGGGTC-3′
P19ARF (F) 5′-GCAGAGCATGGGTCGCAGGTTC-3′ 295
(R)5′-CGGGAGAGGGTGGTGGGGTC-3′
CYCLIN D1 (F) 5′-AATGCCAGAGGCGGATGAGA-3′ 189
(R) 5′-GCTTGTGCGGTAGCAGGAGA-3′
CYCLIN E (F) 5′-TTACTGATGGTGCTTGCTCC-3′ 136
(R) 5′-GTCGTTGACGTAGGCCACTT-3′
Cyclophilin (F) 5′-GGGAAGGTGAAAGAAGGCAT-3′ 211
(R) 5′-GAGAGCAGAGATTACAGGGT-3′
CD 90 (F) 5′-CCAGTCATCAGCATCACTCT-3′ 374
(R) 5′-AGCTTGTCTCTGATCACATT-3′
CD 34 (F) 5′-TGTCTGCTCCTTGAATCT-3′ 281
(R) 5′-CCTGTGGGACTCCAACT-3′
CD 71 (F) 5′-ATGGTTCGTACAGCAGCAGA-3′ 182
(R) 5′-CGAGCAGAATACAGCCATTG-3′
CD 29 (F) 5′-ACTTCAGACTTCCGCATTGG-3′ 190
(R) 5′-GCTGCTGACCAACAAGTTCA-3′
CD 45 (F) 5′-ATGTTATTGGGAGGGTGCAA-3′ 175
(R) 5′-AAAATGTAACGCGCTTCAGG-3′
Table 1 Primer sequences for
Q-RT-PCR and RT-PCR and
product size
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investigated genes have an initial denaturation 95°C,
10 min followed by 45 cycles (for all target genes) and
35 cycles (for housekeeping cyclophilin) of denaturation
for 30 s at 94°C, annealing for 30 s at 60°C (for TERT,
cdk4, cyclin A and Bmi-1), at 55°C (for cyclin B1, cdk6,
cdk2, cdk1, RB, p21 and cyclophilin), at 65°C (for cyclin
D1 and p53), at 59°C (for cdc25A and cyclin E), at 62°C
(for p16INK4a), at 68°C (for p19ARF), followed by extension
of 30 s at 72°C. Final extension at 72°C for 5 min was
applied to all the reactions.
Protein Isolation and Quantification
MSCs were scraped from the cell culture plates in 1x PBS
and the precipitate was treated with a lysis buffer contain-
ing 0.05 M Tris HCl, 1x protease inhibitor, 0.25 M NaCl
and 1% (v/v) IGEPAL for 30 min on ice. Then the lysate
was centrifugated for 20 min at 13,000 rpm at 4°C. Protein
concentrations of supernatants were determined with
Bradford protein assay as described [16].
Western Blotting
The proteins were separated on 8% SDS-PAGE and
transferred to a polyvinylidene fluoride membrane. The
membrane was blocked with blocking solution for 1 h at
room temperature and was incubated in antibody solution at
the concentration of 1:200 (for Bmi-1, TERT, Cdc25a,
Cyclin A, Cdk4, Cyclin D1, Cyclin E), 1:1000 (for Cdk1,
Cdk2, Cyclin B1, p53), 1:2000 (for Cdk6, α-Tubulin) for o/
n at 4°C. Then horseradish peroxidase-linked secondary
antibodies were applied for 1 h in blocking solution.
Finally, Super Signal West Femto Maximum Sensitivity
Substrate (Thermo Scientific, IL, USA) was applied to the
membrane for 5 min and placed in an X-ray film cassette
and developed. Anti-Bmi-1, TERT, Cdc25a, Cyclin A,
Cdk4, Cyclin D1, and Cyclin E antibodies were purchased
from Santa Cruz (Santa Cruz, CA, USA). Anti-Cdk1, Cdk2,
Cyclin B1 and p53 antibodies were purchased from Cell
Signaling Technology (Danvers, MA, USA). Anti-α-Tubulin
antibody was purchased from Calbiochem (Darmstadt,
Germany).
Estimation of Telomerase Activity Using Telomeric Repeat
Amplification Protocol Assay (TRAP)
1×106 MSCs were collected by trypsinization and a
telomerase assay was performed by using TRAP-eze
Telomerase Detection Kit (Millipore, MA, USA). A gel-
based assay was performed for visualization of the
telomeric repeats after PCR, according to the manufac-
turer’s protocol. Gels were stained with SYBR Green I
(Sigma, MO, USA) at 1:10000 dilution in TAE and
visualized with Vilber Lourmat ChemiCapture (Marne-La-
Vallée Cedex, France).
Adipogenic Differentiation
An adipogenic induction medium was prepared by freshly
adding 1 µM dexamethasone (Sigma), 10 µg/ml insulin
(Sigma), 100 µM indomethacin (Sigma) and 0.5 mM
IBMX to LG-DMEM (HyClone), containing 1x penicillin-
streptomycin (HyClone) and 10% FBS (HyClone). The
MSCs were cultured for 21 days, changing the medium
every 2 days with freshly prepared medium. After 21 days
the cells were fixed with 4% paraformaldehyde and stained
with Oil Red O (Sigma).
Osteogenic Differentiation
An osteogenic induction medium was prepared by freshly
adding 0.1 µM dexamethasone (Sigma), 0.2 mM ascorbic
acid 2-phosphate (Sigma) and 10 mM glycerol-2-
phosphate (Sigma) to LG-DMEM (HyClone), containing
1x penicillin-streptomycin (HyClone) and 10% FBS
(HyClone). The MSCs were cultured for 21 days,
changing the medium every 2 days for freshly prepared
medium. After 21 days the cells were fixed with 70%
ethanol and stained with Alizarin Red S (Sigma).
Statistical Analysis
All data are expressed as means ± SD. Data were analyzed
by performing a paired t- test using Minitab Statistical
Software ® (State College, Pennsylvania, USA). A value of
P<0.05 was considered to be statistically significant.
Results
We first investigated the phenotypic effect of GRN163L on
MSCs (Fig. 1). Untreated control MSCs (Fig. 1a) and
mismatch oligonucleotide treated MSCs (Fig. 1b) showed
normal phenotypes with fibroblastic morphology and
spindle-shaped cells. At the same time, when MSCs were
plated in the presence of single dose of 1 μM GRN163L
(163L), we observed phenotypic effects as early as 3 days
after the treatment, such as the cells losing their fibroblastic
shapes, rounding up, and appearing to detach from the plate
surface (Fig. 1c). However, when the drug was removed
and the cells were given time to recover (163LR),
GRN163L-treated MSCs reattached to the plate surface
and regained their normal phenotype within 1 week
(Fig. 1d). By using RT-PCR, we showed that all of the
experimental groups were positive for mesenchymal stem
cell markers (CD29, CD71 and CD90) and negative for
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hematopoietic cell markers (CD34, CD45) (Fig. 1e). We
also examined telomerase activity of MSCs from control,
163L, mismatch and 163LR groups by the TRAP assay
(Fig. 2). The telomerase activity of the MSCs in the 163L
group was completely inhibited, whereas inhibition was not
observed in the mismatched, 163LR or control MSCs. The
effect of GRN163L on telomerase activity was reversible
because the telomeric repeats were also observed in the
163LR group with a similar pattern as in the untreated
control MSCs (Fig. 2a). No telomeric repeats were present
when cell extracts were heat inactivated (Fig. 2b).
To illustrate if after the removal of the ligand whether
MSCs regain their differentiation properties, we induced
lipidogenic (Fig. 3) and osteogenic (Fig. 4) differentiation
Fig. 1 The effect of GRN163L
a Untreated control MSCs
(control); b Mismatch
oligonucleotide treated MSCs
(mismatch); c 1 µM GRN163L
treated MSCs (163L); d MSCs
that were treated, and then left
for 1 week without the ligand
(163LR); e The expression
of the markers of MSCs
(CD90, CD29 and CD71) and
hematopoietic cells (CD34,
CD45)
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in 163LR and compared them to that of control group.
These results show that MSCs are able to differentiate into
adipocytes (Fig. 3c) and osteocytes (Fig. 4c) after they
recovered from the GRN163L treatment, similar to the
MSCs from the control group (Figs. 3a and 4a). We did not
observe differentiation of MSCs from control and 163LR
groups into adipocytes or osteocytes when these cells were
cultured in non-inducing media (Figs. 3b, d and 4b, d
respectively).
As the MSCs cease growing in the presence of
GRN163L and then regain their growth abilities when the
drug was removed, the expression of cell cycle genes
(cyclin A, B, D and E and their counterparts, cdk 1, 2, 4 and
6) were checked both at the mRNA with qRT-PCR (Fig. 5)
and protein level with Western blotting (Fig. 6). In addition,
cdc25A, p16, p19, p21, p53, RB, TERT and Bmi-1 levels
were also investigated. The expression of all the tested
genes were found to decrease upon 163L treatment,
compared to the control group at the mRNA level. Among
those genes, the decrease was statistically significant in the
expression of cyclin D1, cdk6, cyclin E, cyclin B1, cdc25A,
Bmi1, p21and p19 (Fig. 5; control vs 163L). Interestingly,
the expression of all the genes increased in the 163LR
group where the ligand was removed and the MSCs
recovered. Among these genes the increase was significant
in the expression of cdc25A, p53, p21 and p19 (Fig. 5;
163L vs 163LR). The effect of the ligand appears telomerase
Fig. 2 TRAP assay of MSCs from control, mismatched, 163L and
163LR groups. A549 lung cancer cell line was used as a positive
control to determine the telomerase inhibition by 163L. Cell extracts
were prepared from a normal and b heat inactivated samples
Fig. 3 Oil Red O staining
to determine adipogenic
differentiation of MSCs. a
control and c 163LR group by
using induction media. MSCs
from b control group and d
163LR groups did not induce
adipogenic differentiation
when non-induction media
was used
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inhibition specific, since the expression of these genes in the
mismatch group did not decrease (Fig. 5; 163L vs
mismatch). The expression of all the genes, except cyclin
B1 and RB, which were higher than the control group
(Fig. 5; control vs mismatch). A similar pattern of
expression, that is, to decrease upon the 163L treatment
and to increase 1 week after the removal of 163L was also
observed in the expression of some of these genes at the
protein level (Fig. 6). Our Western blot results showed that
the expression of Cdk2, Cdk4, Cdk6, Cyclin D1, and Bmi-
1 decreased in the 163L group compared to the control
group (Fig. 6; control vs 163L) and increased 1 week after
the removal of 163L (Fig. 6; 163L vs 163LR). In contrast,
the expression of Cyclin E and Cdc25A were similar in
control and 163L groups, however, they increased after
163L was removed (Fig. 6; 163L vs 163LR). Other
proteins that were tested did not show any difference
between the groups.
Fig. 4 Alizarin Red S staining
to determine osteogenic differ-
entiation of MSCs. a control
and c 163LR group by using
induction media. MSCs from
b control group and d 163LR
groups did not induce
osteogenic differentiation
when non-induction media
was used
Fig. 5 mRNA expression of
cell cycle genes in MSCs from
control, mismatch, 163L and
163LR groups determined with
qRT-PCR. * indicates p≤0.05
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Discussion
The use of anti-telomerase agents as cancer therapeutic
agents is still in an early stage for complete analyses of
clinical outcomes, efficacy, tolerance and toxicity on
normal tissue [17]. Potential effects of the inhibition of
telomerase activity on stem cells are important because
different stem cell compartments have different levels of
telomerase activity [18]. Embryonic stem cells express high
levels of telomerase activity [19] while several adult stem
cell compartments, such as hematopoietic stem cells,
epidermal stem cells, neural stem cells and mesenchymal
stem cells also maintain telomerase activity but with low
levels [9, 18, 20].
Among these stem cells, the effect of telomerase
inhibitor GRN163L on mesenchymal stem cells is an issue
of potential concern when applied to tumor tissue in vivo
because MSCs emerge as an important player of cell-based
therapies in a wide variety of pathologies, including
cardiovascular disease and myocardial infarction (MI),
brain and spinal cord injury, cartilage and bone injury,
Crohn’s disease and graft-versus-host disease (GVHD)
during bone marrow transplantation [15, 21]. In vivo bone
formation potential of telomerase-over expressing hMSCs
was highly enhanced suggesting telomerase is required for
both cell replication and differentiation [22]. Moreover,
mouse MSCs with their telomerase activity knocked-down
completely failed to differentiate into adipocytes or chon-
drocytes [23]. Thus, one could speculate that hMSCs may
express at least a low level of telomerase activity to carry
out the regenerative capacity as well as the differentiation
potential [18]. Treatment with a telomerase inhibitor could
have unwanted side effects on MSCs. While the potential
side effects are unknown, they are expected to be mild
because stem cell populations have longer telomeres than
tumor cells, and as they divide rarely, their telomeres
should shorten at a much slower rate than proliferating
cancer cells [24].
The present study was undertaken to investigate the in
vitro effects of GRN163L on the self-renewal and differ-
entiation processes of MSCs. First, we evaluated the
morphological changes of MSCs upon treatment of
GRN163L. Previous studies have shown that rapid mor-
phological changes occur within 24 h in cancer cells when
plated in the presence of GRN163L and cells become
rounded up, loosely attached to the surface, cease growing
and die [25, 26]. These morphological changes were
independent of telomerase inhibitory effect of GRN163L
via hTR antagonism, but related to the lipidation of the
compound, the nitrogen-phosphorous-sulfur–containing
backbone chemistry (NPS linkage) and the presence of
triple-G motif. It has also been suggested that antimetastatic
effects of GRN163L may be related with the anti-cell
adhesive effects of this novel cancer therapeutic agent [25].
In our study, similar to the data reported for cancer cell
lines, we observed similar morphological changes when
MSCs were plated in the presence of GRN163L, suggesting
a similar mechanism of action of GRN163L both in MSCs
and cancer cells. The cells’ rounding effects were observed
within 24 h after GRN163L treatment (Fig. 1c), whereas
mismatch oligonucleotide-treated MSCs became tightly
attached to the cell culture plate, similar to the untreated
control cells (Fig. 1b and a, respectively). Moreover,
“rounding effect” was not observed when GRN163L was
withdrawn (163LR group) and they regained the original
mesenchymal stem cell morphology as the unreated control
group (Fig. 1d).
MSCs play an important role in the homeostasis of
organisms therefore GRN163L would not be predicted to
cause any alteration in the long term irreversible differen-
tiation potential of MSCs. To address this issue, we treated
MSCs with GRN163L, let them recover for 1 week and
then evaluated their osteogenic and adipogenic differ-
Fig. 6 Protein expression of cell cycle genes in MSCs from control,
163L and 163LR groups determined by Western blot
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entiations (Figs. 3 and 4, respectively). Our results showed
that there was no noticeable difference in the potential of
these MSCs to differentiate into adipocytes and osteocytes
when compared with the untreated control cells. Observing
of no measurable effects on the differentiation of MSCs
upon GRN163L treatment is of particular clinical impor-
tance, mainly for older patients. Aging deteriorates the
differentiation potential of MSCs [27, 28]; therefore to use
GRN163L for anti-cancer treatment of the elderly would
seem not further decrease the potential.
Several studies have examined telomerase activity in
MSCs, providing somewhat differing results. As discussed
in Sethe et al. 2006, some studies find no telomerase
activity in MSCs, whereas others have detected telomerase
activity [29]. Our results clearly showed that MSCs do have
telomerase activity, and the activity is inhibited by
GRN163L (Fig. 2). Importantly, telomerase activity recov-
ers upon withdrawal of GRN163L (Fig. 2; 163LR group).
The reason for this disparity could be explained by the
presence of the heterogeneous group of MSCs (telomerase
positive and negative) and it clearly warrants further
research [30, 31]. The difference could also be related to
the passage number of MSCs used. It has been recently
shown that telomerase activity is present at 10 days but
negative at 30 days [32]. The MSCs that were used in this
study derived from the first passage and were physiolog-
ically more relevant.
As the “rounded” MSCs were not able to proliferate as
much as the untreated cells, several cyclins and cdks that
regulate cell cycle were analyzed to determine whether
telomerase inhibition leads to cell cycle arrest. Our real-
time PCR and Western blot data clearly showed that
inhibiting telomerase activity with GRN163L does leads
to cell cycle arrest at the G1 phase, and that importantly,
these effects were reversible. Therefore, it is possible to
conclude that the MSCs will regain their proliferation and
self-renewal capacity following the cessation of anti-
telomerase therapy. Additionally, the mismatch oligonucle-
otide had no effect on the proliferation status of these cells,
indicating high specificity of this compound.
It is also important to note that the in vitro effects of
GRN163L on MSCs may not necessarily reflect their
possible in vivo effects. When the telomerase activity was
knocked down, mouse MSCs failed to differentiate into
adipocytes or chondrocytes [23]. On the other hand
telomerase-over expressing hMSCs had been shown to
have a high osteogenic differentiation potential [22].
Systemic effects of telomerase inhibition on bone marrow-
derived MSCs might be different than in vitro reversible
effects. Therefore, new studies are warranted to investigate
the role of GRN163L on in vivo conditions.
In summary, we have investigated the potential effects of
GRN163L on MSCs. Our results suggest that the inhibitory
effect of GRN163L on mesenchymal stem cells is revers-
ible in under short term in vitro cell culture conditions. We
conclude that hTR antagonist GRN163L does not interfere
with the self-renewal and differentiation of MSCs and can
be used without apparent toxic side effects. Nevertheless, in
clinical settings anti-telomerase cancer treatment should be
stopped before telomere depletion in stem cells, so that
telomerase activity and telomeres in reproductive and stem
cells can be restored. Our study provides additional support
for treating cancers by administrating GRN163L without
depleting the body’s stem cell pools.
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